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Pluripotency is the ability of a cell to differentiate into derivatives of all three 
somatic lineages and germ cells. In vivo, pluripotent cells exist transiently in the 
epiblast of the developing embryo and in rare tumour cells.  In vitro, pluripotent 
cells have been isolated and propagated from teratocarcinomas (EC cells), pre-
implantation epiblast (ES cells) and post-implantation epiblast (EpiSCs). 
Pluripotency is governed by a gene regulatory network centred on the triumvirate 
of transcription factors Oct4, Sox2 and Nanog. Interestingly, transcription factors 
that are important to direct pluripotent cell identity are not all equally distributed 
throughout the pluripotent cell population. While Oct4 levels are relatively 
homogeneous, other transcription factors, such as Nanog, are more heterogeneously 
expressed. Additionally, an increasing body of evidence indicates that extrinsic cues 
also play a critical role in the establishment and maintenance of pluripotency.  
Using biochemical and genetic tools in mouse ES cells, the role of FGF 
signaling and Sox2 levels on heterogeneous Nanog expression was examined. 
Interference with FGF or ERK activity by genetic ablation or signal inhibition, 
promoted high, homogenous Nanog expression and enhanced self-renewal. This is 
consistent with reports showing that similar manipulations reduced the ability of ES 
cells to commit to differentiation. Moreover, ES cells with reduced Sox2 levels 
displayed greater heterogeneity for Nanog expression than wild-type ES cells.  
Pluripotency is lost in the mouse embryo around E8.5, however, the precise 
timing and mechanism involved in this process has not yet been defined. Here it is 
shown that pluripotency is extinguished at the onset of somitogenesis, coincident 
with reduced expression and chromatin accessibility of Oct4 and Nanog regulatory 
regions. Prior to somitogenesis, the expression of both Nanog and Oct4 is 
regionalized. Interestingly, pluripotency tracks the in vivo level of Oct4, this 
correlation does not hold true for Nanog. However, Nanog expression reports on 
pluripotent cells. Indeed, ectopic Oct4 expression in somitogenesis-stage tissue 
provokes rapid reopening of Oct4 and Nanog chromatin, Nanog re-expression and 
resuscitation of moribund pluripotency. Competence to re-activate the pluripotency 
network upon enforced Oct4 expression is gradually lost with the progression of 
embryonic development.  
ES cells and EpiSCs are two distinct pluripotent populations as they show 
differences in their ability to undergo clonal propagation, re-colonize embryos, 
growth factor responsiveness, morphology and gene regulatory networks. It is 
possible to harness this differential growth factor responsiveness to convert ES cells 
into EpiSCs. Conversely, EpiSC can be reverted back to ES cell pluripotency through 
the overexpression of a small number of transcription factors. The inter-conversion 
of ES cells and EpiSCs has been documented, but detailed analyses of the changes 
that occur during such transitions had not been performed. The current work shows 
that Nanog levels are critical for the specification of the pluripotent state of the cells. 
Furthermore, it is shown that orphan nuclear receptor Esrrb is a potent inducer of 
ES cell pluripotency in EpiSC. Interestingly, Esrrb was able to restore naïve 
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1.1 Stem cells 
Although a consensus has not been reached on a general definition for the 
term “stem cell”, the prevailing view is that stem cells are cells with the ability to 
undergo long-term self-renewal and that can generate at least one type of 
specialized descendant. Self-renewal is the division of a cell to produce two 
daughter cells, out of which, at least one is identical to the parental cell. On the other 
hand, differentiation occurs when a cell becomes more specialized and losses 
proliferative capacity. In the majority of the cases, stem cells do not produce a 
terminally differentiated cell, but instead produce intermediate/progenitor cell(s) 
that display a more restricted proliferative and differentiation capacity (Gardner 
and Beddington, 1988; Guo et al., 2010). 
 
1.2 Pluripotency 
The ability of a single cell to generate every cell type in the adult organism 
has been termed as pluripotency (Smith, 2005, 2006). In order to ensure proper 
growth and differentiation during embryonic development, the timing and location 
of pluripotent cells must be tightly regulated. In vivo, pluripotent cells exist 




cells. The following pluripotent cells have been isolated: embryonal carcinoma (EC) 
cells, embryonic stem (ES) cells, embryonic germ (EG) cells and post-implantation 
epiblast stem cells (EpiSCs). These pluripotent cells have the following origins: EC 
cells were isolated from teratocarcinomas, ES cells from the inner cell mass (ICM) of 
blastocysts, EG cells from primordial germ cells (PGCs), and EpiSC were derived 
from the post-implantation epiblast (Brons et al., 2007; Evans, 1972; Evans and 
Kaufman, 1981; Martin, 1981; Matsui et al., 1992; Resnick et al., 1992; Tesar et al., 
2007).  
 
1.3 Pluripotent populations 
1.3.1 EC cells 
In the 1970s an observation was made that set down the foundation for 
pluripotent cell biology. This observation was that certain type of tumours, now 
known as malignant, contained an undifferentiated component able to seed a new 
tumour when transplanted into a secondary recipient. These original experiments 
were performed using tumours that spontaneously arise in the testes of mice 
(Stevens, 1960, 1964; Stevens and Little, 1954). Malignant tumours, also known as 
teratocarcinomas, are a mass of cells consisting on a chaotic mixture of 
differentiated derivatives of the three germ layers and undifferentiated stem cells. 
The stem cells present in teratocarcinomas were named as embryonal carcinoma 
due to their resemblance to embryonic tissue. Subsequent experiments performing 
transplantations of pre-gastrulation embryos into kidney capsules or testes 
demonstrated, that the origin of teratocarcinomas was not restricted to male germ 




was shown that the cellular origin of the teratocarcinoma forming potential of pre-
gastrulation embryos was the epiblast (Diwan and Stevens, 1976). The formal 
confirmation that EC cells are pluripotent stem cells was obtained through the 
observation that their clonal transplantation could generate secondary 
teratocarcinomas (Kleinsmith and Pierce, 1964). EC cells could be propagated in 
vitro through explant culture, readily generating stable EC cell lines (Finch and 
Ephrussi, 1967). Moreover, EC cell lines retain the ability for multilineage 
differentiation in teratocarcinoma assays. Interestingly, when EC cells were 
reintroduced into pre-implantation embryos these cells were able to contribute to 
the hosts’ tissues, thereby generating chimeric embryos and/or live animals 
(Brinster, 1974; Papaioannou et al., 1978; Papaioannou et al., 1975). This indicates 
that prolonged self-renewal of EC cells is not a malignant transformation, but it is 
rather a tightly controlled process that can be aborted at any point in response to the 
appropriate differentiation cues. However, the pressure for selective growth 
advantage during the propagation of EC cells compromises their genetic 
constitution. Indeed, the majority of EC cells are aneuploid, such genetic aberrations 
results in restricted differentiation potential and reduced ability to contribute to 
chimaeras.  
 
The ground-breaking work performed studying EC cells was pivotal for the 
subsequent isolation of pluripotent cells from the embryo proper. A critical point 
was the finding that pluripotent cells heavily benefitted by their co-culture with 
fibroblasts (Martin and Evans, 1975).  The same authors later reported the isolation 
of pluripotent stem cells lines from mouse blastocyst (Evans and Kaufman, 1981; 




EC cells.  However, it soon became apparent that the embryo-derived stem cells 
were qualitatively different, given the observation that when put back into pre-
implantation embryos these stem cells readily contributed to chimaeras and the 
germline (Bradley et al., 1984). To denote their tissue of origin, these cells were 
named embryonic stem cells. 
 
1.3.2 Mouse embryonic stem cells 
  ES cells are a pluripotent population isolated from mice at embryonic days 
3.5-4.5 (E3.5-4.5). The tissue of origin of ES cells is the naïve epiblast, which is a cell 
layer present in the ICM of mouse blastocysts. The derivation and culture of ES cells 
has been achieved using combinations of cytokines, growth factors, hormones, 
serum, serum extracts, conditioned media and feeders. Regardless of the preferred 
culture conditions, stimulation with the leukemia inhibitory factor (LIF) remains a 
common practice in the routine culture of mouse ES cells. Extrinsic factors used for 
the propagation of ES cells have been identified for their specific ability to stimulate 
or protect the gene regulatory network controlling pluripotency. Considerable 
evidence indicates that ES cell self-renewal and pluripotency is governed by a 
transcriptional network centred on Oct4, Sox2 and Nanog (Boyer et al., 2005; Chen 
et al., 2008; Loh et al., 2006). These master nuclear regulators target genes encoding 
transcription factors, signal transduction components and chromatin-modifying 
enzymes that promote self-renewal, while suppressing differentiation (Avilion et al., 
2003; Chambers et al., 2003; Chambers et al., 2007; Chambers and Tomlinson, 2009; 




1.3.3 Post-implantation epiblast stem cells 
The mouse embryo at the implantation stage is composed of the epiblast and 
the extra-embryonic tissues. The later consists of the extra-embryonic ectoderm and 
endoderm, which will give rise to the placenta and yolk sac respectively. The 
epiblast is a pluripotent derivative of the ICM. After implantation the epiblast 
undergoes dramatic expansion and morphogenesis, resulting in its transformation 
from an unstructured cell mass into a columnar epithelium. The post-implantation 
epiblast is subject to potent lineage specifying signals from adjacent extra-
embryonic tissues. Recently it was shown that pluripotent stem cells could be 
derived from the epiblast layer of post-implantation mouse embryos (Brons et al., 
2007; Tesar et al., 2007). When EpiSC were used in embryoid body and teratoma 
formation assays these cells were shown to be capable of differentiating into 
derivatives of all three primary germ layers, thereby proving their pluripotent 
identity (Brons et al., 2007; Tesar et al., 2007). Additionally, EpiSCs express the core 
pluripotency transcription factors Oct4, Sox2 and Nanog (Brons et al., 2007; Tesar et 
al., 2007). Despite expressing Oct4, Sox2, and Nanog, differences in the transcription 
factor circuitry strongly suggests that ES and EpiSC are two distinct pluripotent 
states (Bao et al., 2009; Brons et al., 2007; Han et al., 2010; Tesar et al., 2007). For 
example, T-brachyury, a marker of primitive streak and tail bud, is detected at 
higher levels in EpiSC when compared to ES cells (Tesar et al., 2007). It is therefore 
possible that some EpiSC populations reflect an in vivo state reminiscent of the 
primitive streak, in which cells are pluripotent but primed for germ layer 
differentiation. Notably, EpiSCs display culture requirement and properties similar 




EpiSCs and hES cells is promoted by the stimulation of TGF/Activin/Nodal 
signaling pathway (Amit et al., 2004; Brons et al., 2007; James et al., 2005; Tesar et al., 
2007; Vallier et al., 2009). It has been proposed that pluripotency in hES cells and 
mouse EpiSC is sustained by activation of Activin/Nodal signaling. Furthermore, 
Nanog activation has been identified as the mechanisms through which 
Activin/Nodal signaling promotes pluripotent identity in hES and EpiSC (Greber et 
al., 2008; Greber et al., 2010; Vallier et al., 2009; Xu et al., 2008). Nanog has been 
reported to inhibit neural differentiation in hES cells (Vallier et al., 2009). 
Interestingly, ES cells have no absolute requirement for Nanog in the maintenance 
of pluripotency (Chambers et al., 2007). Moreover, EpiSCs differ from ES cells in the 
fact that they have flattened colony morphology, inefficient clonal propagation and 
a limited capacity for colonising pre-implantation embryos (Brons et al., 2007; Han 
et al., 2010; Tesar et al., 2007). Based on the previous differences it has been 
proposed that there two pluripotent states, naive (ES cells) and primed (EpiSC) 
pluripotency (Nichols and Smith, 2009). Throughout this work the terms naive and 
primed pluripotency are used to refer to the potency of ES cells and EpiSC, 
respectively.  
 
1.3.4 Embryonic germ cells 
EG cells are pluripotent cells derived from PGCs (Brons et al., 2007; Evans, 
1972; Evans and Kaufman, 1981; Martin, 1981; Matsui et al., 1992; Resnick et al., 
1992; Tesar et al., 2007). PGC precursors are specified from the proximal posterior 
epiblast at day E6.25. The proximal epiblast acquires germ cell competence in 




Therefore, it is likely that anterior-posterior axis specifying signals such as Nodal 
and Wnt antagonists play an important role in the specification of the germ cell 
lineage. In this regard, Smad2 mutants, which show an abnormal expression of 
Nodal and FGF8 throughout the epiblast present ectopic clusters of germ cells 
(Waldrip et al., 1998). PGCs can readily be identified from the proximal posterior 
epiblast by the expression alkaline phosphatase, Fragilis, Stella and Blimp1. 
Interestingly, the expression of pluripotency associated genes Sox2, Oct4 and Nanog 
is retained in PGCs. It is believed that the pluripotency associated factors act in 
cooperation with Blimp1 to suppress the activation of the somatic programme and 
erasure of epigenetic modifications. The established PGCs proliferate and migrate 
from the base of the allantois to reach the genital ridges at E11.5. During this period 
PGCs undergo a gradual erasure of the parental imprinting during their migration 
to the genital ridges, this is a critical step in restoring totipotency to the germline 
(Kato et al., 1999). Finally, once in the genital ridges, PGCs differentiate into germ 
cells.   
 
Teratocarcinomas have been reported to spontaneously arise from germ cells 
(Stevens, 1960, 1964; Stevens and Little, 1954). However, the direct evidence of the 
pluripotent identity of germ cells remained anecdotal until the in vitro isolation of 
germ cells. In this regard, the cloning of LIF and steel growth factor proved to be 
pivotal for germ cell isolation (Matsui et al., 1991; Smith et al., 1988; Williams et al., 
1988). Furthermore, it was also shown that supplementation of bFGF allowed for 





1.3.5 Induced pluripotent stem cells  
Takahashi and Yamanaka (2006) published a ground-breaking study 
showing that somatic cells could be induced to re-acquire an ES cell-like state. 
Indeed, the ectopic expression of Oct4, Sox2, cMyc and Klf4 and Sox2 is sufficient to 
induce pluripotency, albeit at low frequency and over a long time period, in 
terminally differentiated cell types. These reprogrammed cells are known as 
induced pluripotent stem (iPS) cells. Initially these cells were not able to generate 
germline competent adult chimaeras, this was only achieved once the reactivation of 
endogenous Nanog or Oct4 were used to screen for successful reprogramming 
(Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007). Understanding the 
mechanism through which Oct4, Sox2, cMyc and Klf4 promote the induction of 
pluripotency is a key focal point for the iPS field. 
 
1.3.5 Reprogramming of EpiSC 
ES cells pluripotency can be restored in EpiSC by the overexpression of 
several ES cell transcription factors: Klf4, Klf2, Nr5a receptors, Nanog or activation 
of Jak/Stat3 activity (Guo and Smith, 2010; Guo et al., 2009; Hall et al., 2009; Silva et 
al., 2009; Yang et al., 2010). The overexpression of these factors alone is not sufficient 
to re-establish the ability to colonize pre-implantation embryos, but must be 
accompanied by a media switch. A pre-requisite for the induction of naïve 
pluripotency in EpiSC is the removal of the growth factors Activin and FGF (Hall et 
al., 2009), suggesting that in the majority of the cases, extrinsic cues have a dominant 
effect over intrinsic factors during EpiSC reprogramming. EpiSCs, co-cultured with 




was achieved by the inhibition of mitogen-activated protein kinase (MEK; 
(PD0325901)) and/or glycogen synthase kinase 3 (GSK3; (CHIR99021)) signaling in 
EpiSC propagated on feeders (Greber et al., 2010). 
 
LIF stimulation is crucial for the propagation of mouse ES cells (Smith and 
Hooper, 1987). EpiSC, on the other hand, respond poorly to LIF stimulation (Hall et 
al., 2009). This could be due partly, to the low levels of expression of components of 
the LIF/Stat3 signaling pathway or the absence of Stat3 partner proteins. In support 
of the first hypothesis, the ectopic expression of GY118F (chimeric receptor which 
induces the hyperactivation of JAK/Stat3) or Stat3 overexpression can revert EpiSC 
to ES pluripotency (Hall et al., 2009). This suggests that a competent LIF/Stat3 
pathway is a limiting factor in the ability of cells to incorporate into pre-
implantation embryos. Moreover, the overexpression of Klf4, a Stat3 target gene, 
can restore naïve pluripotency in EpiSC (Guo et al., 2009). Interestingly, EpiSC 
reprogramming efficiency is increased when Stat3 activation is combined with MEK 
(PD0325901)/GSK3 (CHIR99021) inhibition and ectopic Klf4 expression (Hall et al., 
2009). The enhanced reprogramming efficiency of EpiSC observed by the ectopic 
expression of Klf4, in combination with activated Stat3, suggests that other Stat3 
target genes may also contribute to the reprogramming process. Interestingly, 
another Klf family member, Klf2 has recently been shown to be able to revert EpiSC 
to naïve pluripotency. Unlike Klf4, Klf2 is not regulated by LIF-Stat3 signaling 
pathway. On the other hand, it has been demonstrated that Klf2 is a direct Oct4 





Nr5a1 and Nr5a2 are orphan nuclear receptor whose function in pluripotent 
cells remains poorly understood. Nr5a2 has been reported to be able to replace Oct4 
during somatic cell reprogramming (Heng et al., 2010). The reprogramming ability 
of the Nr5a receptor is intriguing, considering that these genes are not expressed in 
EpiSC and have no apparent role in ES cell self-renewal (Gu et al., 2005; Guo and 
Smith, 2010). It has been shown that Nr5a2 is necessary for the maintenance of Oct4 
expression in the post-implantation epiblast (Gu et al., 2005). Moreover, it has been 
speculated that Nr5a2 also plays a role in the activation of Oct4 expression in ES 
cells (Masui et al., 2007). In a reprogramming context, Oct4 expression alone is 
insufficient to revert EpiSC to naïve pluripotency (Guo and Smith, 2010), this is an 
indication that the reprogramming activity of the Nr5a receptors acts also through 
an alternative mechanism.  
 
Nanog has been reported to be essential for the acquisition of ground state 
pluripotency. Cells lacking Nanog can never acquire potency similar to that 
observed in the pre-implantation epiblast (Silva et al., 2009). In the context of 
somatic cell reprogramming through cell fusions, Nanog enhances reprogramming 
efficiency (Silva et al., 2006). Moreover, Nanog is also a potent inducer of ES cell 
pluripotency in EpiSC (Silva et al., 2009). Furthermore, Nanog is able to promote the 
reversion of EpiSC to naïve pluripotency in culture conditions that are not 





1.4 Somatic Pluripotency 
A defining feature of the amniote epiblast is its ability to produce all three 
embryonic germ layers and their differentiated derivatives, a property known as 
somatic pluripotency. The potency of a specific cell or tissue can be assayed by 
transplantation of the cell/tissue to ectopic sites in adult mice, such as the kidney 
capsule or testes, to test their differentiation potential. In this assay, a cell or tissue is 
pluripotent if it has the ability to generate teratocarcinomas. These tumours contain 
undifferentiated, pluripotent stem cells called EC cells and many differentiated 
tissues, including representatives of all three germ layers (Skreb et al., 1991). Using 
the teratocarcinoma assay it has been reported that somatic pluripotency in the 
mouse is lost at some point between the start of gastrulation (E7.5) and early 
organogenesis (E8.5) (Damjanov et al., 1971). After this time, embryonic cells are 
reported to be unable to form teratocarcinomas. It has also been shown that at E7.5 
the different regions of the epiblast remain pluripotent (Beddington, 1983). 
Differentiation is thought to occur progressively in a rostral-to-caudal sequence. In 
part, this matches the expression pattern of the Oct4 (Yeom et al., 1996).  Its 
disappearance in a rostral-to-caudal direction suggests that the primitive streak, at 
the posterior end of the embryo, retains pluripotent cells for longest.  Heterotopic 
grafts of E7.5 epiblast have been reported to support this idea, as fragments of 
anterior epiblast transplanted to distal or posterior sites in the E7.5 embryo show 
slightly less capacity to adapt to their new location and differentiate appropriately 
than ectopically grafted distal or posterior epiblast (Beddington, 1982; Beddington, 
1981). Although all grafts show a degree of both adaptation to their new 




support of the idea of a rostral-to-caudal sequence of commitment during 
gastrulation, up to E7.5.  
 
Interestingly, somatic pluripotency is accompanied by the expression of key 
transcription factors known to regulate pluripotency in ES cells. These factors 
include Oct4 (Yeom et al., 1996), Sox2 (Avilion et al., 2003; Wood and Episkopou, 
1999) and Nanog (Hart et al., 2004; Hatano et al., 2005). Sox2 expression is well 
documented and its expression continues long after E7.5 (Avilion et al., 2003; Wood 
and Episkopou, 1999), however, the expression of Oct4 and Nanog has not been 
monitored carefully over this period. 
 
1.5 Factors governing self-renewal 
 Self-renewal in stem cells depends on extrinsic and intrinsic factors. The 
balance between extrinsic and intrinsic determines cell potency and fate. Intrinsic 
factors include cell autonomous components, whereas, extrinsic factors are external 
signals that control cell fate.  
1.5.1 Intrinsic factors governing self-renewal 
In the context of stem cell self-renewal, intrinsic regulators include cell 
autonomous components such as proteins involved in signaling transduction and 
nuclear factors controlling gene expression, protein modulation and chromatin 
modifications. Transcription factors can dramatically affect cell fate through the 
global regulation of gene expression, for this reason, these nuclear regulators receive 
particular attention. Transcription factors are traditionally defined as proteins that 




genes and promote transcription. In other words, these factors control gene 
expression, therefore affecting cellular function and fate. In general terms, 
transcription factors interact with each other at different levels and make up 
complex networks. The majority of these networks, including the pluripotency 
network, follow a hierarchical organization. This implies that the relative influence 
of each factor on the system is not identical. There are some factors that only affect a 
small number of network components, whereas other factors exert their influence 
on the majority of the elements that make up the network. 
 
1.5.1.1 Oct4 
Oct3/4 is POU containing transcription factor that is expressed in 
pluripotent populations and multipotent somatic progenitors (Nichols et al., 1998; 
Yeom et al., 1996). This homeodomain protein has been reported to be essential for 
the formation of the ICM (Nichols et al., 1998). It has been suggested that POU 
factors can interact with themselves forming homodimer or with other proteins to 
form heterodimers (Remenyi et al., 2003; Remenyi et al., 2001). Some of the proteins 
that are reported to interact with Oct4 are Sox2, -catenin, Dax1 and Nanog 
(Ambrosetti et al., 1997; Ambrosetti et al., 2000; Sun et al., 2009; Takao et al., 2007; 
Wang et al., 2006). Additionally, Oct4 is a transcriptional regulator that can 
activate/repress target genes. Oct4 target genes in ES cells include: Oct4, Opn, 
FGF4, Utf1, Fbx15, Nanog, Zfp42 (Rex1), Esrrb, Lefty1, Cdx2 and Sox2 (Ben-Shushan 
et al., 1998; Botquin et al., 1998; Catena et al., 2004; Dailey et al., 1994; Nakatake et 
al., 2006; Nishimoto et al., 1999; Niwa et al., 2005; Tokuzawa et al., 2003; van den 
Berg et al., 2008; Wang et al., 2006; Zhang et al., 2008). Oct4 levels are critical for the 




of Oct4 is necessary to sustain ES cell self-renewal, however, a two fold increase in 
the levels of this transcription factor causes differentiation into primitive endoderm, 
while repression induces dedifferentiation into trophectoderm (Niwa et al., 2000). 
On the other hand, the interaction of Oct4 with Cdx2 has proven to be essential in 
the specification of cell fate in the blastocyst. Overexpression of Cdx2 in ES cells 
results in the repression of ES specific transcripts and differentiation into 
trophectoderm. Notably, Oct4 and Cdx2 interact at the protein and DNA level 
forming a reciprocal repression complex, in which the balance of Oct4/Cdx2 
determines cell fate (Niwa et al., 2005). 
 
1.5.1.2 Sox2 
Sox2 belongs to the family of SRY (Sex-related HMG box) transcription 
factors that contain one HMG-box that binds DNA. Moreover, Sox2 interacts with 
Oct4 at the protein and DNA level (Ambrosetti et al., 1997; Ambrosetti et al., 2000). 
Interestingly, the majority of the pluripotency associated genes contain enhancers 
that possess Oct4/Sox2 binding motifs. Hints into the functionality of these 
enhancers are revealed by the fact that in undifferentiated ES cells they are highly 
active (Kuroda et al., 2005; Nakatake et al., 2006; Nishimoto et al., 1999; Tokuzawa et 
al., 2003; Yuan et al., 1995). Oct4 and Sox2 bind independently to their motifs, but 
synergistically activate the enhancers.  
Sox2 deletion in the embryo is lethal at the post-implantation stage. In the 
absence of Sox2 the only surviving cells at this stage are giant trophoblast cells and 
extra-embryonic endoderm, however, this phenotype can be rescued by injection of 
wildtype ES cells (Avilion et al., 2003). This result suggests that Sox2 plays a critical 




results in their differentiation into multiple lineages (Ivanova et al., 2006). However, 
a more rigorous analysis of Sox2 function in ES cells, using an inducible genetic, 
results in their differentiation into trophectoderm, reminiscent of the phenotype 
observed in Oct4 deletion. Notably, the phenotype observed following Sox2 could 
be rescued by expression of an Oct4 transgene (Masui et al., 2007).  A more detailed 
analysis revealed that Sox2 is necessary in ES cells to sustain expression of Oct4 
(Masui et al., 2007). The previous results suggest that Sox2 functions to stabilize 
Oct4 expression in ES cells.    
 
1.5.1.3 Nanog 
Nanog is a divergent homeodomain protein with the ability to confer 
cytokine-independent self-renewal to ES cells. It is first expressed in the early mouse 
embryo (morula, ICM and epiblast) and is permanently silenced from somatic cells 
at late head-fold stage, shortly before somitogenesis. It has been suggested that 
Nanog is necessary for the specification of naïve epiblast and germ cells. Recent 
studies imply that Nanog may have an essential role in the establishment of the 
pluripotent state, but is thereafter dispensable for its maintenance. ES cells that have 
been depleted of Nanog can self-renew indefinitely in vitro and retain pluripotency. 
It has been speculated that Nanog protein acts as a differentiation rheostat in 
pluripotent cells while improving their self-renewal ability (Mullin et al., 2008; Silva 







The estrogen related receptor-β (Esrrb) is an orphan nuclear receptor that 
has been reported to be an important component of the intricate pluripotency 
network (Chen et al., 2008; Ivanova et al., 2006; Kim et al., 2008; Loh et al., 2006; van 
den Berg et al.; van den Berg et al., 2008; Wang et al., 2006; Zhang et al., 2008). 
Previous studies have shown that pluripotency associated factors bind the 
regulatory region of the Esrrb gene (Chen et al., 2008; Ivanova et al., 2006; Kim et al., 
2008; Loh et al., 2006; van den Berg et al.; van den Berg et al., 2008; Wang et al., 2006; 
Zhang et al., 2008). Nanog has been documented to interact with a range of partner 
proteins, among these interacting proteins is Esrrb (Wang et al., 2006; Zhang et al., 
2008). Moreover, Esrrb has also been reported to interact at the protein level with 
Oct4, this interaction has been suggested to be important in the regulation of Nanog 
(van den Berg et al., 2008). Estrogen related receptor- has also been shown to be 
essential in the self-renewal of mES cells (Ivanova et al., 2006; Loh et al., 2006) and 
also capable of somatic cell reprogramming when ectopically expressed in 
conjunction with Oct4 and Sox2 (Feng et al., 2009). Direct evidence for the role of 
Esrrb in ES cell self-renewal was obtained by the observation overexpression of this 
factor promotes cytokine independent self-renewal (Zhang et al., 2008).  
Nevertheless, the regulation of Esrrb in ES cells and the mechanisms through which 
Esrrb sustains pluripotency remain poorly understood. 
 
1.5.1.5 Klf4 
The Kruppel-like factor 4 (KLF4), also known as gut-enriched KLF, is a 
member of the Kruppel-like family of transcription factors. The Kruppel-like factors 




segmentation gene, Kruppel (Schuh et al., 1986). Klf4 is expressed in ES cells and pre-
implantation embryos (Guo et al., 2009; Li et al., 2005) and it has been shown to be a 
target of LIF/Stat3 signaling (Li et al., 2005; Niwa et al., 2009), suggesting that it 
may mediate the positive effects LIF stimulation. Direct evidence that it plays a role 
in ES cell self-renewal comes from the observation that Klf4 overexpression 
decreases differentiation in embryoid bodies (EB) and enhances the ability to 
generate secondary (Li et al., 2005). Notably, cytokine independent self-renewal can 
be achieved by Klf4 overexpression in ES cells (Hall et al., 2009). It has been 
reported that Klf4 cooperates with Oct4/Sox2 to activate Lefty1 expression 
(Nakatake et al., 2006). Moreover, comparative analysis of global gene expression 
following Oct4 deletions and Klf4 knockdown, showed a modest overlap between 
Oct4 and Klf4 target genes (Nakatake et al., 2006). Indeed, genome-wide chromatin 
immunoprecipitation (ChIP) analyses of ES cells revealed that Klf4 shares many 
common targets with the core pluripotency factors Nanog, Oct4 and Sox2 (Chen et 
al., 2008). Interestingly, it was shown that somatic cells could be reprogrammed to 
pluripotency by transfection with the transcription factors Oct4, Sox2, c-Myc and 
Klf4 (Takahashi and Yamanaka, 2006). Nonetheless, it was later demonstrated that 
cMyc and Klf4 are dispensable for the generation of iPS cells but their inclusion 
enhanced the speed and efficiency of the process (Nakagawa et al., 2008; Yu et al., 
2007). Klf4 has also been shown to be capable of reverting EpiSCs to ES cell 
pluripotency (Guo et al., 2009). The previous observations provide further support 
to the notion that Klf4 plays a significant role in the regulation of naïve 
pluripotency. However, Klf4 knockdown in ES cells does not have a blatant 
phenotype, since alkaline-phosphatase immuno-reactivity and undifferentiated 




mice results in perinatal lethality due to the loss of skin barrier function and 
deficiencies in globlet cell differentiation (Katz et al., 2002; Segre et al., 1999). The 
lack of a blatant phenotype in Klf4-/- embryos and knockdown in ES cells may 
suggest that Klf transcription factors show functional redundancy. Consistent this 
notion, other members of the Klf family, such as Klf1, Klf2, and Klf5, can substitute 
for Klf4 in somatic cell reprogramming (Nakagawa et al., 2008). Furthermore, triple 
knockdown of Klf2, Klf4 and Klf5 results in ES cell differentiation, while single 
knockdowns did not exhibit blatant phenotypes (Jiang et al., 2008). Together, these 
results strongly suggest that Klf family members may play similar roles in the 
establishment and maintenance of naïve pluripotency. In summary, Klf4 forms part 
of the intricate network sustaining pluripotency, however, its precise role in ES cell 
self-renewal and maintenance of pluripotency remain poorly defined. 
 
1.5.2 Extrinsic factors governing ES cell self-renewal 
The original isolation of mouse ES cells was achieved using culture 
conditions used for routine propagation of EC cell lines. Such conditions involved 
the co-culture of pluripotent cells with inactivated fibroblast in serum-containing 
media (Evans and Kaufman, 1981; Martin, 1981). Given the observations that 
clonogenicity and self-renewal of pluripotent cells was enhanced under such 
conditions, it was believed that this effect was mediated by trophic factors secreted 
by fibroblasts. For this reason, inactivated fibroblasts are hence known as feeders. 
Further support for this notion was obtained by the observation that feeders could 
be replaced by the addition of medium conditioned by buffalo rat liver cells (Smith 




conditioned medium (Smith et al., 1988; Williams et al., 1988). The combination of 
LIF and serum-containing media is sufficient to support self-renewal of 
undifferentiated cells. However, the active components present in serum remain 
allusive for quite some time. A ground-breaking study finally showed that bone 
morphogenetic protein 4 (BMP4) could replace serum, allowing for the first time the 
propagation of ES cells in fully defined conditions (Ying et al., 2003a). Given the 
observation that the propagation of pluripotent cells requires extrinsic signals, it is 
of particular interest to establish the link  between intrinsic and extrinsic regulator 
mediating self-renewal in pluripotent cells.    
 
1.5.2.1 LIF-Stat3 
LIF belongs to the IL6 family of cytokines, all of which, signal through a 
common transmembrane receptor, gp130 (Boulton et al., 1994). In the presence of 
serum, stimulation of gp130 homodimers (Yoshida et al., 1994) or heterodimers 
(such as gp130 + LIF receptor) promotes ES cell self-renewal. Moreover, two main 
signaling pathways become activated following ligand-induced receptor 
dimerization. First, the intracellular domain of gp130 interacts with Janus kinases 
(JAKs) (Boulton et al., 1994) and subsequently, JAK phosphorylates the tyrosine 
residues on the intracellular domain of gp130. This phosphorylation is responsible 
for the generation of binding sites for STAT3. Once bound, STAT3 is 
phosphorylated on Tyr705 by JAKs, promoting subsequent dimerization and 
translocation to the nucleus where it directs transcription of target genes. 
Elimination of the tyrosine residues of gp130 essential for STAT3 binding abolished 
self-renewal activity (Niwa et al., 1998). Moreover, the overexpression of a fusion 




when activated with exogenous tamoxifen (Matsuda et al., 1999). These experiments 
show that the critical target directing self-renewal through gp130 signaling is 
STAT3. Furthermore, STAT3 homodimers function as transcription factors. It is 
important to mention that the pluripotent epiblast forms normally in gp130-/- 
mutant embryos (Yoshida et al., 1996). Therefore, the in vivo requirement for 
gp130/STAT3 signaling in pluripotent cells remains unclear.  
 
1.5.2.2 BMP4 
Bone Morphogenetic Proteins (BMPs) are morphogens that play critical roles 
during embryonic development. In the context of ES cells, BMP4 has been shown to 
block neural differentiation (Ying et al., 2003a). Moreover, it was shown that BMP 
signaling acts through SMAD1, 5 and 8 to induce the expression of inhibitor of 
differentiation (ID) proteins. Confirmation that ID proteins mediate BMP function 
was obtained by the demonstration that constitutive expression of ID1, ID2 or ID3 
can replace the requirement for BMP or serum for the propagation of ES cells (Ying 
et al., 2003a). It was also demonstrated that ES cells could be derived and 
propagated efficiently in chemically defined media (N2B27) supplemented 
exclusively with LIF and BMP4 (Ying et al., 2003a).  
 
1.5.2.3 Wnt/GSK3 
Wnt signaling has been reported to be involved in a vast number of 
functions in tissue homeostasis and development. There are two types of Wnt 
signaling pathways, canonical and non-canonical. Canonical Wnt signaling involves 
the presence of -catenin, while non-canonical Wnt signaling operates without it. In 




an interaction leads to activation of Dishevelled. Subsequently, activated 
Dishevelled prevents the destruction complex from phosphorylating -catenin, 
which is the signal necessary to target such protein for proteolysis. Therefore, 
inactivation of the destruction complex results in stabilization and nuclear 
accumulation of -catenin. It has been shown that GSK3, a component of the 
destruction complex, is the kinase responsible for -catenin phosphorylation. 
Furthermore, it was also demonstrated that direct inhibition of GSK3 could mimic 
Wnt signaling (Finlay et al., 2004). The role of Wnt signaling in ES cell self-renewal 
and differentiation has been a topic of debate due to contradictory findings (Del 
Valle et al., 2013; Haegele et al., 2003; Lyashenko et al., 2011; Otero et al., 2004; Wray 
et al., 2011). It has recently been demonstrated that canonical Wnt signaling is 
dispensable for ES cell self-renewal, but necessary for their differentiation into 
mesendodermal and neural lineages (Lyashenko et al., 2011; Wray et al., 2011). 
However, it has also been shown that GSK3 inhibition enhances ES cell self-renewal, 
through the modulation of Tcf3 (Wray et al., 2011). In vivo, -catenin function is 
essential in anterior-posterior axis formation in the mouse (Huelsken et al., 2000). 
 
1.5.2.4 ERK1/2 
Mitogen activated protein kinases (MAPKs) have been implicated in the 
control of a great range of cellular processes. Two MAPKs, extracellular signal-
regulated protein kinase-1 and -2 (ERK1/2), have been implicated in the regulation 
of early embryonic cell fate choice and ES cell self-renewal (Buehr and Smith, 2003; 
Burdon et al., 1999; Kunath et al., 2007; Lanner and Rossant, 2010; Saba-El-Leil et al., 




MEK1/2 works upstream of ERK1/2. MAPKs are involved in the transduction of 
several extracellular cues, prominent among these, is the FGF signaling pathway. In 
brief, FGFs interact with its membrane bound receptors, which in turn induce the 
activation of the receptor tyrosine kinase, promoting the recruitment first of the SH2 
domain containing proteins (Shp2/Grb2), and subsequently, son of sevenless 
homolog (SOS). This results in the induction of Ras, stimulating the MAPK cascade, 
which culminates with the activation of ERK1/2. It has been hypothesized that 
upon activation, ERK1/2 can act on cytoplasmic targets and/or translocate to the 
nucleus to activate transcription of its target genes (Marais et al., 1993; Yang et al., 
2012).  
 
Further evidence for the role of MEK in fate of mouse ES cells was obtained 
from the observation that during EB differentiation, MEK inhibition, prevents Oct4 
downregulation (Burdon et al., 1999). Interestingly, FGF4-/- ES cells (Wilder et al., 
1997) have been shown to display enhanced self-renewal. Furthermore, ES cells 
lacking functional Fgf4 or Erk2 failed to differentiate under conditions that normally 
promote neural differentiation, or in the presence of BMP4, which normally 
promotes non-neural differentiation (Kunath et al., 2007). The differentiation 
deficiency of Fgf4-null ES cell could be rescued by the addition of recombinant 
FGF4, demonstrating that the loss of autocrine FGF4 signaling is responsible for this 
phenotype (Kunath et al., 2007). Previous reports have shown that the activity of 
FGF/MAP kinase signaling pathway is essential for embryonic development, 
probably through its key role in the specification of early lineages in pre-
implantation embryos (Chazaud et al., 2006; Feldman et al., 1995; Kang et al., 2013; 




implantation (Feldman et al., 1995), prior to this, the ICM of these embryos were 
exclusively composed of Nanog-positive cells (Kang et al., 2013).  Embryos lacking 
functional Grb2 are unable to generate the primitive endoderm (PrE). Moreover, the 
ICM of Grb2-null embryos lack the mutually exclusive pattern of Gata6 and Nanog, 
which mark PrE and epiblast progenitors respectively, but instead display uniform 
Nanog expression (Chazaud et al., 2006). Interestingly, inhibition of FGF/MAP 
kinase signaling promotes epiblast formation, whereas excess FGF instructs the 
formation of primitive endoderm (Nichols et al., 2009; Yamanaka et al., 2010). The 
emerging view is that FGF signaling is critical for early lineage segregation in pre-
implantation embryos and ES cells, probably through limited availability of soluble 
FGF and differential expression of FGF receptors in individual cells.  
 
1.5.2.5 2i 
It has recently been reported that ES cells can be efficiently propagated in 
well-defined media by the inhibition of differentiation inputs provided by ERK and 
GSK3 signaling (Ying et al., 2008). Thus, showing for the first time that, when 
shielded from differentiation cues, the pluripotency network can direct robust self-
renewal in mouse ES cells. When cultured using the two inhibitors (2i), ES cells 
exhibit distinct gene expression and epigenetic features (Marks et al., 2012). A 
practical consequence is that it has become facile to establish ES cells from different 
strains of mice and also rats (Blair et al., 2011). It is noteworthy that, while the triple 
combination of 2i/LIF appears optimal, mouse ES cells can be propagated by 
providing any two of these three components (Wray et al., 2011), implying 





1.5.3 Extrinsic factors governing EpiSC cell self-renewal 
1.5.3.1 TGF/Activin/Nodal 
The transforming growth factor- (TGF) signaling pathway is involved in 
numerous cellular processes in the developing embryo and adult organism. TGF 
superfamily of ligands includes: growth and differentiation factors, TGFβ, Activin, 
BMPs and anti-mullerian hormone. TGF super-family of receptors bind to its 
specific ligands, such interaction promotes the downstream signaling which include 
the phosphorylation of Smad2/3 (Shi and Massague, 2003). TGFβ signaling has been 
shown to be essential for the maintenance of pluripotency in hES cells and mouse 
EpiSCs (Amit et al., 2004; Brons et al., 2007; James et al., 2005; Tesar et al., 2007; 
Vallier et al., 2004). It has also been shown that MEF-conditioned medium can 
support the propagation of hES cells (Xu et al., 2001). A later study demonstrated 
that the active component promoting the propagation of mouse EpiSCs and hES 
cells cultured in MEF-conditioned medium was Activin (Greber et al., 2010). The 
previous finding is supported by reports showing that pharmacological inhibition 
of the TGF signaling pathway, results in the differentiation of mouse EpiSCs and 
hES cells (Greber et al., 2010; James et al., 2005; Wu et al., 2008). Recent studies have 
shown that TGF signaling acts through Smad2/3 to activate Nanog expression in 
mouse EpiSCs and hES cells (Greber et al., 2010; Vallier et al., 2009; Xu et al., 2008). 
Notably, long-term propagation of mouse EpiSC and hES cells requires 
supplementation with both Activin and FGF (Brons et al., 2007; Greber et al., 2010; 
Tesar et al., 2007; Vallier et al., 2004; Xu et al., 2005). The conserved role of TGFand 




evolutionary importance of these signaling pathways in the generation and 
propagation of pluripotent cells in mammals (Brons et al., 2007; Dvorak et al., 2005; 
James et al., 2005; Tesar et al., 2007; Vallier et al., 2004; Xu et al., 2005). 
 
1.5.3.2 FGF 
FGF2, also known as basic FGF, is now routinely added to the media for 
culture of hES cells and mouse EpiSC (Brons et al., 2007; Levenstein et al., 2006; 
Tesar et al., 2007; Xu et al., 2005). hES cells have been reported to be able to produce 
distinct isoforms of FGF2 and express several FGF receptor (Dvorak et al., 2005). 
Furthermore, inhibition of the FGF receptors in hES cells results in a reduction in 
phosphorylation of MEK1/2 and ERK1/2, followed by Oct4 downregulation and 
differentiation (Dvorak et al., 2005). Moreover, addition of recombinant FGF2 to 
cultures of hES cells does not seem to affect proliferation, but does reduce 
differentiation and the overall colony quality (Dvorak et al., 2005). Although this 
work provides evidence for the requirement of FGF signaling in the maintenance of 
pluripotency of hES cells, the mechanisms involved remain poorly defined. In this 
regard, it has been shown that FGF signalling has a moderate effect on Nanog 
expression in hES cells (Greber et al., 2007; Greber et al., 2010). Remarkably, in the 
mouse counterpart, EpiSCs, FGF signaling fails to support Nanog expression (Greber 
et al., 2010). Interestingly, the previous study also showed that FGF signaling 
stabilizes EpiSC pluripotency by blocking neuroectodermal differentiation and 
preventing de-differentiation into ES cells (Greber et al., 2010). It is quite intriguing 
that FGF signaling has such diverse roles in distinct pluripotent populations (hES 
cells; mouse ES cells and EpiSCs). However, it should be noted that FGF stimulation 




PI3K-AKT. It is probable that any of these signaling pathways could affect the 
balance between self-renewal and differentiation of pluripotent cells. It is therefore 
necessary to dissect the role of these signaling cascades in order to identify their 
precise role in distinct pluripotent populations.  
 
1.6 Cellular heterogeneity 
Several studies have shown that under self-renewal conditions, mouse ES 
cells exhibit considerable heterogeneity in the levels of factors such as Nanog, Stella, 
Rex1, Pecam1, Tbx3 and Klf4 (Chambers et al., 2007; Furusawa et al., 2006; Hayashi 
et al., 2008; Toyooka et al., 2008). One could imagine that cellular heterogeneity 
reflects an irreversible developmental progression. However, sorting of single cells 
and monitoring their subsequent behaviour in culture have established that such 
heterogeneous states are reversible. For instance, it has been shown that within the 
undifferentiated sorted Nanoglow cells can give rise to a Nanoghigh cells and vice versa 
(Chambers et al., 2007). Cellular heterogeneity could be advantageous during 
embryonic development as a mechanism that provides flexibility to the 
differentiation process.  In this context, the balance of key transcription factors 
prompts differentiation along specific lineages when the correct cue arises. In ES 
cells low levels of Nanog result in pre-disposition towards differentiation, whereas 
high levels of Nanog present a bias towards self-renewal (Chambers et al., 2003; 
Chambers et al., 2007). Since Nanog is at the cusp of the pluripotency network and 
has the ability to modulate ES cell self-renewal, studying the origin of Nanog 






Materials and Methods 
 
2.1 Culture and manipulation of mouse ES cells 
2.1.1 Routine culture 
2.1.1.1 Media 
For preparation of complete ES media, Glasgow Minimal Essential Media 
(GMEM; Sigma) was supplemented with -mercaptoethanol (BDH), sodium 
pyruvate/L-glutamine (Invitrogen), Foetal Calf Serum (FCS; Invitrogen), non-
essential amino acids (Gibco) as indicated below. Leukemia Inhibitory Factor (LIF; 
in house) was added to 100U/ml.  
GMEM/-mercaptoethanol/10%FCS (hereafter referred to as GMEMFCS): 
 500ml   GMEM 
 11ml   Sodium pyruvate (1mM)/L-glutamine (2mM) 
 51ml   FCS  
 5.5ml   Non-essential amino acids (100x) 







Gelatin (Sigma) was dissolved in Dulbecco PBS (Sigma) to a concentration 
of 0.1% w/v. Flasks/plates were covered with 0.1% gelatin in PBS for a minimum of 
5-10 minutes at room temperature. Gelatin was aspirated and cells plated 
immediately. 
 
Laminin was used as a substrate for ES cells that attached poorly in serum-
free media. Briefly, flasks/plates were covered with poly-L-ornithine 0.01% (Sigma) 
and incubated at 4C overnight. Poly-L-ornithine was aspirated and flasks/plates 
washed twice in PBS. Flasks/plates were then covered with laminin (Millipore) 5 
mg/ml in PBS and incubated at room temperature for at least 2hr. Laminin was 
aspirated and replaced with media until ready to use. 
 
2.1.1.3 Supplements and cytokines 
Serum is the liquid fraction of clotted blood from fetal calf, depleted of cells, 
fibrin and clotting factors, but contains a large number of nutritional and 
macromolecular factors that promote survival and proliferation. Bovine serum 
albumin is the major component of the fetal bovine serum. FCS (Invitrogen) was 
diluted to a final concentration of 10% for routine culture of ES cells.    
 
LIF was generated in-house by transient transfection of COS7 cells with plasmid 
encoding human LIF. Following 4 days, the conditioned media was harvested, 




2.1.1.4 Reagents for passaging of ES cells 
ES cells were passaged enzymatically using a 1x trypsin solution. The 
preparation was as follows, 0.186g of EDTA was dissolved in 500ml PBS and filter 
sterilised. Next, 5ml of trypsin (2.5%; Invitrogen) and chicken serum (Sigma) were 
added and subsequently mixed. The trypsin solution was stored at -20C.  
Protocol 
ES cells were cultured as described in (Smith, 1991). Media was changed every 
day with pre-warmed GMEMFCS/LIF. Cells were routinely passaged once they 
reached a confluency of 70-80% as follows: 
1. Pre-treated tissue culture flasks/plates (Iwaki) were coated with 0.1% gelatin  
(Sigma)/Dulbecco PBS (Sigma) for 5-10 minutes before passaging cells. 
2. ES cell media was removed from the flask/plates via aspiration.  
3. Cells were washed once with pre-warmed Dulbecco PBS (Sigma), such 
solution was subsequently aspirated.  
4. Trypsin solution was added to the cells. The volume of the trypsin solution 
varied depending on the type of flask/plate used. For maximal recovery 
cells it is essential that the monolayer be entirely covered with the trypsin 
solution. 
5. The flask/plate was placed at 37C/7% CO2 incubator for ~3 minutes.  
6. In order to dislodge the cells the flask/plate was gently tapped. 
7. Trypsin was inactivated by addition of 4x volume of GMEMFCS.  
8. The cells were transferred to a centrifuge universal tube and centrifuged at 
1200rpm for 3 minutes (ALC PK120; Annita). 
9. The supernatant was aspirated and the cells pellet was resuspended in 10ml 




10. Routinely the cells were split 1:10 at each passage into pre-warmed 
GMEMFCS/LIF.  
11. Cells were returned to the 37C/7% CO2 incubator. Flasks were left with a 
loose cap to ensure that the cells received CO2. 
 
2.1.2 Propagation in serum-free media supplemented with LIF 
and GSK3/MEK inhibitors 
2.1.2.1 Media 
Serum-free media, prepared as described (Ying et al., 2003b), is composed of 
a 1:1 mixture of Neurobasal (Gibco) and DMEM/F12 (Gibco), supplemented with -
Mercaptoethanol (BDH), L-glutamine (Invitrogen), N2 (Gibco) and B27 (Gibco). The 
proportions and quantities mixed were as follows: 
N2B27  
 1:1   Neurobasal:DMEM/F12  
 2mM   L-glutamine 
 1:200   N2 
 1:100   B27 
 0.1 M   -Mercaptoethanol 
 
2.1.2.2 Inhibitors 
Long-term propagation of ES cells in serum-free media was performed as 
described in (Ying et al., 2008) by supplementation of N2B27 with LIF and two small 




GSK3 was achieved using 3 M CHIR99021 (Stemgent). MEK inhibition was 
achieved using 1M PD0325901 (Stemgent).  
2i/LIF   See Ying et al., 2008 
 N2B27 
 LIF (100U/ml) 
 CHIR99021 (3 M) 
 PD0325901 (1M) 
 
Protocol 
ES cells were cultured in serum-free media supplemented with 2i/LIF as 
described (Ying et al., 2008). Media was changed every other day using pre-warmed 
N2B27/2i/LIF media. Cells were routinely passaged once that they reached a 
confluency of 70-80%. 
1.  Flasks/plates coated with gelatin or laminin as described in section 2.1.1.2. 
2-8. These steps were identical to the protocol in section 2.1.1.4.   
9.     The supernatant was aspirated and the cells pellet was resuspended in  
        N2B27/2i/LIF media and routinely split 1:10.  
10.   Cells were returned to the 37C/7% CO2 incubator. Flasks were left with a  





2.1.3 Long-term storage of mouse ES cells 
For long-term storage mouse ES cells can be frozen and kept in liquid 
nitrogen at a temperature of ~170C. Cells were harvested by enzymatic dissociation 
(trypsin). A minimum of 2-3 million cells was resuspended in 1-0.5ml of freezing 
mix (GMEMFCS/LIF containing 10% dimethyl-sulphoxide (DMSO)). The mixture 
was then transferred into a 1ml cryotube (Nunc). Vials were placed immediately at -
80C and after overnight storage transferred to liquid nitrogen. 
 
2.1.4 Thawing mouse ES cells 
Cryotubes were taken out of the liquid nitrogen storage (cell bank) and 
transferred immediately to the waterbath (37C) to thaw. The thawed cells were 
then diluted with 9ml of pre-warmed GMEMFCS/LIF and transferred into a 
centrifuge universal tube. The cells were pelleted via centrifugation at 1000rpm for 






Table 2. 1 Antibiotics concentrations used for drug selection in 
mouse cells. 
Antibiotics Stock [  ] Working [  ] Supplier 
Zeocin 100mg/ml 200g/ml Gibco 
Blasticidin-S 5mg/ml 5-10g/ml Invitrogen 
Hygromycin-B 50mg/ml 100-200g/ml Roche 
G418 200mg/ml 200g/ml PAA 
Puromycin 5mg/ml 1-2g/ml Sigma 
 
2.1.5 Transfection of DNA into mouse ES cells  
2.1.5.1 Stable transfection 
ES cells at a density below 85% were used for stable transfections as follows: 
1. Media was changed 2h prior to the electroporation. 
2. 100mm diameter plates were gelatinized (see section 2.1.1.2).  
3. 9ml of GMEMFCS/LIF was added and the plates placed in a 37C/7% CO2 
incubator to equilibrate. 
4. ES cells were collected by enzymatic dissociation as described in section 
2.1.1.4. 
5. Cells were centrifuged at 1200rpm for 3 minutes (ALC PK120; Annita).  
6. The cell pellet was washed twice with pre-warmed PBS.  
7. Cells were resuspended in 10ml of PBS and counted using a 
haemocytometer. 




9. The cell pellet was resuspended in a volume of 0.6ml PBS (1x). 
10. 0.1ml of PBS (2x) was added to the 0.6ml of cell suspension. 
11. 100g of DNA (linearized with a restriction enzyme that cuts in the plasmid 
backbone) was resuspended in 0.1ml of PBS (1x) and transferred into an 
electroporation cuvette (Biorad). 
12. The cell suspension was added to the electroporation cuvette (Biorad) 
containing the DNA and mixed gently. 
13. The electroporation cuvette was left 3 minutes at room temperature. 
14. Electroporation was performed at 0.8kV and 3F using a GenePulser 
(Biorad).  
15. The cell suspension was collected using a plugged Pasteur pipette and 
mixed with 9.2ml of pre-warmed GMEMFCS/LIF.  
16. 1ml of the cell suspension (106 cells) was added to the 100mm plates 
containing 9ml of pre-warmed and equilibrated GMEMFCS/LIF. 
17. The 100mm plates were swirled and placed in the 37C/7% CO2 incubator. 
18. Antibiotic selection was added to the culture 24-30h post-transfection.  
 
2.1.5.2 Episomal transfection 
1. 106 cells were plated into a well of gelatinised 6-well plate in a volume of 2ml 
of GMEMFCS/LIF. 
2. The 6-well plate was placed in a 37C/7% CO2 incubator for 30 minutes 
prior to the transfection.  
3. 3l of Lipofectamine 2000 (Invitrogen) was diluted into 250l of 




4. 3g of plasmid DNA was diluted into 250l of GMEM and incubated at 
room temperature for 5 minutes. 
5. The Lipofectamine 2000 and DNA solutions were mixed and incubated at 
room temperature for 20 minutes. 
6. The DNA/Lipofectamine mixture was added gently and slowly to the well 
with plated cells. 
7. The 6-well plate was swirled to ensure proper mixing. 
8. The 6-well plates were put back into the 37C/7% CO2 incubator. 
9. The following day the transfected cells were replated and selection was 
started.  
 
2.1.6 Picking ES cell colonies 
ES cell colonies were picked once that the emerging colonies were visible 
with the naked eye. Media was then aspirated and cells washed twice with pre-
warmed PBS. A very small volume of PBS was left on the 100mm dishes to ensure 
that the cells did not dry out. 30l of trypsin was taken up using a 200l pipette. The 
tip containing the 30l of trypsin was carefully placed over the desired colony. The 
30l of trypsin was expelled over the colony. Next, the colony was scraped and 
sucked up with the 200l pipette. The trypsinised cells were then seeded into a 
gelatinised well of a 96-well plate (Iwaki), which contained ~200l of 
GMEMFCS/LIF. The pipette was used for further mechanical dissociation of the 






2.1.7 Clonal assays  
2.1.7.1 Stable transfections  
Clonal assays were routinely performed by seeding 600 cells into a 
gelatinised well of a 6-well plate. Cells were cultured in a 37C/7% CO2 incubator 
for 6 days in the presence or absence of LIF. After 6 days the cells were fixed and 
stained for alkaline phosphatase (see section 2.1.8).    
 
2.1.7.2 Episomal supertransfections 
Clonal assays were routinely performed by seeding at a density of 5 x 104 or 
2 x 105 into a gelatinised 100mm plate. Cells were cultured in a 37C/7% CO2 
incubator in the presence of the appropriate selection and with or without LIF for 
10-12 days. After 10-12 days the cells were fixed and stained for alkaline 
phosphatase. 
 
2.1.8 Alkaline phosphate staining 
This was performed using an alkaline phosphatase kit (86R-1KT, Sigma).  
 
2.1.8.1 Fixative solution 
 25ml Citrate solution (18mM Citric acid; 9mM Sodium citrate; 12mM NaCl) 
 8ml Formaldehyde 






400l FRV alkaline solution and 400l Sodium nitrate solution were mixed 
and incubated for 2 minutes at room temperature. The Alkaline/Nitrate was added 
to 18ml dH2O. Finally, 400l of Napthol solution was added. 
Protocol 
1. Media was aspirated. 
2. The cells were washed twice with pre-warmed PBS. 
3. Fixative solution was added for 45s (with enough volume to cover the 
bottom of the well/plate).  
4. The fixative solution was removed and the cells were washed with dH2O.  
5. The stain was added with enough volume to cover the bottom of the 
well/plate and incubated for 25 minutes at room temperature in the dark. 
6. The stain was removed and wells were washed with dH2O. 
7. Plates were allowed to dry before subsequent analysis.  
 
2.1.9 FACS analysis 
ES cells were collected from the plates/flask using enzymatic dissociation 
(trypsin). The pellet was resuspended in ice-cold PBS/10% FCS at a density of ~106 
cells. Anti-SSEA1 antibody (mc480IgM, Developmental Studies Hybridoma Bank, 
University of Iowa, U.S.A.) was added at a dilution of 1:1,000 and cells incubated at 
4C for 20 minutes. Next, cells were spun down and washed with PBS/10% FCS. 
Phycoerythrin-conjugated anti-IgM mouse antibody (Jackson Laboratories) was 
added at a dilution of 1:1,000 for 15 minutes at 4C in the dark. To identify the dead 




(Becton Dickinson) and LSRFortessa (Becton Dickinson) were used to capture the 
data and Flowjo software was used for data analysis and presentation. 
 
2.2 Derivation, culture and manipulation of mouse EpiSC 
2.2.1 Routine culture of embryo-derived EpiSC 
2.2.1.1 Media 
Embryo-derived EpiSC were cultured as described (Tesar et al., 2007). 
Embryo-derived EpiSC media (DMEM-F12/KOSR/Activin/bFGF) consisted of 
DMEM-F12 (Invitrogen), 20% Knockout Serum Replacement (KOSR; Invitrogen), 10 
ng/ml basic FGF (bFGF; R&D Systems), 20 ng/ml Activin-A, 2 mM L-glutamine, 0.1 
mM 2- mercaptoethanol, and 1x non-essential amino acids. 
 
2.2.1.2 Substrate 
Murine embryonic fibroblasts (MEFs) were obtained from E13.5 fetuses from 
129/Ola mouse strain. Embryos were dissociated mechanically and by 
trypsinisation before plating on gelatin-coated 100mm diameter dishes in 
GMEMFCS. The outgrowing cells were expanded for a single passage and 
used/frozen. For use as feeders, confluent MEFs were mitotically inactivated either 
by (1) exposure to 10μg/ml Mitomycin C (Sigma, M4287) for 3 hours or (2) 





2.2.2 Derivation of embryo-derived EpiSC 
EpiSC were derived from embryos obtained from different mouse stains 
such as 129/Ola, C57BL/6, 129/Nanog:GFP or B6/129/Gt(ROSA)26Sortm1(rtTA*M2)Jae/ 
Col1a1tm2(tetO-Pou5f1)Jae/J.  
Protocol 
1. Embryos were dissected from their decidua in M2 or PB1.  
2. Reichert's membrane was removed with forceps or glass needles and a cut 
was made at the boundary between the extra-embryonic ectoderm and the 
epiblast with forceps.  
3. The embryonic fragment containing the epiblast and overlying visceral 
endoderm was incubated for 10-15 minutes at 4 °C in a solution of 0.5% 
trypsin and 2.5% pancreatin in PBS.  
4. Embryos were drawn into a hand-pulled glass pipette with a diameter 
slightly smaller than the fragment to peel away the visceral endoderm.  
5. The isolated epiblast fragments were rinsed in PB1 and disaggregated into 
clumps with a very fine glass pipette. For the derivation of 
anterior/posterior EpiSC lines from E7.5-E7.75 each embryo was carefully 
dissected as described in section 2.3.4. Briefly, the anterior/posterior epiblast 
and overlying visceral endoderm was incubated for 10-15 minutes at 4°C in 
a solution of 0.5% trypsin and 2.5% pancreatin in PBS. The epiblast 
fragments and visceral endoderm were rinsed in PB1 and disaggregated into 




6. The embryo fragments were then explanted onto a layer of feeders in wells 
with an area of 1.9 cm2. Primary explants and EpiSC were cultured on 
feeders in DMEM-F12KOSR/Activin/bFGF.  
7. Feeders were seeded at a density of 4.8 x 104 cells per cm2 in GMEMFCS. 
8. Primary explants were passaged every 2–3 days using Accutase. EpiSC were 
passaged every 5-6 days with Accutase.  
9. Cells were incubated with Accutase for 5 minutes and then triturated into 
small clumps of 10–100 cells.  
10. Cells were then resuspended in DMEM-F12/KOSR/Activin/bFGF and 
replated on a layer of feeders in the appropriate culture plates.  
 
2.2.3 Routine culture of ES-derived EpiSC 
2.2.3.1 Media 
ES-derived EpiSC were cultured as described previously (Guo et al., 2009) in 




 Human fibronectin (Sigma) was dissolved in Dulbecco PBS (Sigma) to a 
concentration of 15 µg/ml. Flasks/plates were covered with 15 µg/ml human 
fibronectin in PBS for a minimum of 5-10 minutes at room temperature. Fibronectin 





2.2.4 Derivation of ES-derived EpiSC 
ES-derived EpiSC were generated as described (Guo et al., 2009).  
Protocol 
1. ES cells were plated at a density of 4 x 104 in a 35mm diameter dish (6-well 
plates, Iwaki) with fibronectin.  
2. For the first 24hrs the cells were grown in GMEMFCS and then transferred 
to feeder free EpiSC media (N2B27/Activin/bFGF).  
3. Cells were passaged every 5-7 days; briefly, cells were washed twice with 
PBS and then incubated in 350µl of Accutase (Sigma) for 3-5 minutes. 
4. 3ml of N2B27 was used to dilute the Accutase and collect cells.  
5. Cell suspension was then placed in a universal and spun down for 3 minutes 
at 1400rpm.  
6. EpiSC were replated at a density of 4 x 104 in N2B27/Activin/bFGF.  
 
2.2.5 Long-term storage of EpiSCs 
For long-term storage mouse EpiSCs were frozen and kept in liquid nitrogen 
at a temperature of ~170C. Cells were harvested by enzymatic dissociation 
(Accutase). A minimum of 2-3 x 106 cells was resuspended in 1-0.5ml of KOSR with 
10% DMSO. The mixture was then transferred into a 1ml cryotube (Nunc). Vials 






2.2.6 Thawing mouse EpiSCs 
Cryotubes were taken out of the liquid nitrogen storage (cell bank) and 
transferred immediately to the waterbath (37C) to thaw. The thawed cells were 
then diluted with 4ml of pre-warmed N2B27 media and transferred into a centrifuge 
universal tube. The cells were pelleted via centrifugation at 1000rpm for 3-4 minutes 
(ALC PK120; Annita). 
 
2.2.7 Differentiation of EpiSC using signal inhibition 
EpiSCs were plated at a density of 1 x104. FGF and TGF/Nodal/Activin 
signaling pathway were inhibited using PD0325901 (1M; Stemgent) or SB431542 
(10M; Sigma) respectively. 
 
2.2.8 Reprogramming of EpiSC 
2.2.8.1 Episomal supertransfection 
EpiSC expressing polyoma large T antigen were transfected with 3μg of 
plasmid using Lipofectamine 2000 (Invitrogen; 11668-019). Next day, 5 x 104 cells 
were replated in the presence of the appropriate drug selection and plates stained 
for AP after 7 days. For further analysis, Epi-iPS cell colonies were picked and 
expanded in the absence of selection. 
 
2.2.8.2 Stable transfection 
For stable integration of plasmid DNA into EpiSC, Amaxa Nucleofection 




plasmid DNA was ideally performed with a Cre-revertable plasmid. To establish 
Cre-revertable transgenic EpiSC lines, 5 x 106 RC EpiSC were nucleofected using the 
Amaxa Nuclefection kit (VPH-1001; Lonza) with 10μg of the desired vectors. 
Transfected cells were plated in the appropriate EpiSC culture media and placed 
under antibiotic selection for a period of 5 days. Following selection, cells were 
replated at a density of 2 x 105 into N2B27/2i/LIF in continued drug selection and 
plates stained for alkaline phosphatase after 7 days. For further analysis of reverted 
clones, Epi-iPS cell colonies were picked and expanded in GMEM/FCS/LIF. To 
test clone stability, Cre-mediated excision of the plasmid DNA was performed.  
 
2.2.8.3 Reversion of EpiSC to Epi-iPS in a Nanog-/- background 
5 x 104 EpiN-iNanog and EpiN-iEsrrb cells were replated in 100mm 
diameter dishes in GMEM/FCS/LIF +/- doxycycline and plates stained for AP 
after 7 days. Epi-iPS cell colonies were also picked and expanded in the absence of 
doxycycline.      
 
2.3 Mouse husbandry, staging, culture and manipulation 
of embryos 
2.3.1 Mouse husbandry and staging 
Mouse husbandry was performed by the animal unit staff at the 
ISCR/SCRM. Mice were maintained on a 12 hour light/12 hour dark cycle.  For 
timed mating’s, noon on the day of finding a vaginal plug was designated E0.5. 




embryonic stage variation between and within litters, gastrulation-stage embryos 
were more carefully staged according to (Downs and Davies, 1993), namely: ES, 
early-streak; MS, mid-streak; LS, late-streak; OB, no allantoic bud; EB, early allantoic 
bud; LB, late allantoic bud; EHF, early head fold; LHF, late head fold.   
 
2.3.2 Blastocyst injections and morula aggregations 
Chimaeras were produced by microinjection into C57Bl/6 blastocysts or by 
morula aggregation as described (Schwartzberg et al., 1989). 
 
2.3.3 Embryo culture 
Embryo culture was performed in 50% rat serum as described (Copp, 1990), 
except that embryos were cultured in static 4-well dishes in an incubator at 5% CO2 
in air. 
 
2.3.4 Embryo manipulation (mechanical) 
Embryos were dissected in M2 (Sigma) using a dissecting microscope 
(Olympus SZ40). Sub-regions of the embryo were separated with hand-pulled solid 
glass needles as described (Cambray and Wilson, 2007). To dissect anterior 
(Nanog:GFP negative) and posterior (Nanog:GFP positive) regions of the E7.5 
embryo, embryos were first ordered relative to developmental stage and 
photographed in a fluorescence stereomicroscope to assess GFP positive and 
negative regions. A transverse cut was made to separate the most proximal epiblast, 
containing primordial germ cells, together with the extra-embryonic region, from 




from posterior/proximal regions.  Finally, the embryos were again viewed and 
photographed to check accuracy of micro-dissection.  Where a minority of GFP 
positive cells remained in anterior regions, these were trimmed off and discarded.  
To dissect prospective forebrain and adjacent region, the extra-embryonic 
membranes were removed with forceps and the embryo lay flat dorso-ventrally, 
with the aid of a transverse cut near the node if necessary.  Forebrain and adjacent 
region were then cut with glass needles. 
 
2.3.5 Embryo manipulation (biological) 
Ubiquitous Oct4 expression in somitogenesis-stage tissue was achieved 
using a mouse line carrying both the Doxycycline-inducible reverse tetracycline 
transactivator (rtTA) targeted at the Col1a1 locus, and an Oct4 transgene (TgOct4) 
under the control of a tet-response element, targeted at the Rosa26 locus. 129/Ola 
wild type females were crossed with TgOct4/TgOct4;rtTA/rtTA homozygous male 
mice (B6/129/Gt(ROSA)26Sortm1(rtTA*M2)Jae/ Col1a1tm2(tetO-Pou5f1)Jae/J; (Hochedlinger et 
al., 2005). 
 
2.3.6 Grafting under the kidney capsule 
Engraftments were performed as described by Robertson (1987), with the 
following modifications. Surgical operations were carried out on mice of the same 
strain as the fragments grafted. Grafting was done in a Class II laminar flow hood 
under sterile conditions using a dissecting microscope (Olympus SZ40). Mice were 
anaesthetised with an intra-peritoneal injection of 0.5 ml of Avertin. To reduce the 




peritoneal. An incision was made in the flank on the left side and the corresponding 
kidney exposed. A small tear was made in the kidney capsule using fine forceps and 
fragments were transferred using a glass pipette controlled by mouth suction. The 
kidney was then replaced, the peritoneal cavity sutured and the skin clipped to 
close the wound.  
 
2.3.7 Recovery and processing of kidneys 
Kidneys were processed, fixed and stained as described (Bancroft & Gamble, 
2002). 4-6 weeks after the graft was performed, the mice were sacrificed and the 
kidneys removed in PBS. Growths could be seen by eye or in some cases a 
dissecting microscope was used. After imaging, the growth and the surrounding 
part of the kidney were fixed overnight in 4% PFA/PBS. After fixing, the kidneys 
were dehydrated through ethanol series (2x 5min PBT; 1x 5min 25% methanol/PBT; 
1x 5min 50% methanol/PBT; 1x 5min 75% methanol/PBT; 2x 5min 100% methanol),  
cleared in xylene and embedded in paraffin wax before being sectioned in a 
microtome. Alternatively, for antibody and his to-chemical stains, the tissue was 
sectioned in a Leica cryostat at 5µm.  
 
2.3.8 Isolation of secondary EpiSC from teratocarcinomas 
Tumours were isolated and chopped roughly before dissociation in 0.5% 
trypsin/2.5% pancreatin/PBS and incubation at 37C for 15 minutes. After 
trituration, cells were plated onto MEFs in EpiSC media, passaged the following day 





2.4 Imaging, staining and in situ hybridisation  
2.4.1 Imaging 
Images were captured using Volocity (Improvision) software on a Zeiss 
Stemi SV11 dissecting microscope (whole embryos and kidneys), an Olympus IX51 
(for cultured cells), or an Olympus BX61 (for sections). Image processing was 
performed using Adobe Photoshop software. 
 
2.4.2 Immunohistochemistry of embryos 
Embryos were dissected in PB1 or M2, the extra-embryonic membranes were 
removed to facilitate penetration of the antibodies.  
Protocol 
1. The embryos were fixed using 4% PFA/PBS overnight at 4C.  
2. Permeabilization was achieved using 0.5% Triton X100/PBS for 15 minutes.  
3. Blocking was done overnight at 4C using 3% serum (same species as 
secondary antibody), 1% BSA/PBS/Triton (0.1%).  
4. The primary antibody was diluted appropriately in blocking solution and 
the embryos were incubated with the diluted antibody for 48hrs at 4C.  
5. The embryos were then washed four times with PBS/Triton (0.1%) for 15 
minutes at RT.  
6. The secondary antibodies conjugated to Alexa fluorophores (Molecular 
Probes, Eugene, Oregon, United States) were diluted 1:1000 in blocking 
buffer and the embryos were incubated with the diluted antibody for 3hrs in 




7. Embryos were then washed four times with PBS-Triton (0.1%) for 15 minutes 
at RT.  
 
2.4.3 Immunohistochemistry of cells 
Protocol 
1. Cells were fixed in 4% PFA/PBS for 10 minutes at RT.  
2. Permeabilization was done with PBS-Triton (0.5%) for 15 minutes at RT.  
3. Blocking was performed for 30 minutes at RT using PBST 0.1%/BSA 1%/ 
Serum 3%.  
4. Primary antibodies were diluted in blocking buffer and applied for 1-2 h at 
RT or overnight at 4 °C.  
5. Cells were washed three times in PBS/Triton (0.1%).  
6. Secondary antibodies were diluted 1:1000 in blocking buffer and applied for 
1 h at RT.  
7. The cells were washed at least three times in PBS/Triton (0.1%). 
 
The cells and embryos were then visualized on an Olympus inverted 
fluorescence microscope. Nanog was detected by using an affinity-purified rabbit 
anti-Nanog antibody directed against an amino-terminal epitope 
(SVGLPGPHSLPSSEE; Chambers, 2005), 1:400; Oct4 (sc-5279, Santa Cruz 
Biotechnology), 1:200; Sox2 (sc-17320, Santa Cruz Biotechnology), 1:200; Esrrb (PP-
H6705-00, Persaeus Proteomics), 1:1000; Hnf3B (Foxa2; sc-9187, Santa Cruz 
Biotechnology), 1:200; T-Brachyury (sc-17745, Santa Cruz Biotechnology), 1:400; 





For immunostaining of tumours, paraffin sections were re-hydrated and 
after 15 minutes of antigen retrieval by heating and blocking, sections were 
incubated with anti-Oct4 antibody (1.5 µg/ml, sc-5279, Santa Cruz Biotechnology), 
anti-Tubulin III (Covance; 1/300 dilution) or anti-desmin (D33, DakoCytomation, 
1/50 dilution) overnight. Sections were then washed three times in PBS/0.1%v/v 
TritonX100 and incubated with a secondary biotinylated goat anti-mouse antibody 
(7.5 µg/ml, BA-9200, Vector Laboratories). After 30 minutes of quenching of 
endogenous peroxidise activity using 0.3% H2O2 DAB detection was carried out 
using the Avidin Biotin Complex (ABC) reagent kit (Vector Laboratories) according 
to the manufacturer’s instructions. 
 
2.4.4 In situ hybridization 
Embryos were subjected to whole-mount in situ hybridisation as described 
(Wilkinson et al., 1990) except that proteinase K treatment was empirically adjusted 
between 8-16 minutes according to embryo size and stage. The riboprobes used 
were: Oct4 (Scholer et al., 1990a) and Nanog (Chambers et al., 2003). The T7 or Sp6 
polymerase site was used to transcribe antisense riboprobe. Embryos were 
dehydrated via an ethanol series (2x 5min PBT; 1x 5min 25% methanol/PBT; 1x 
5min 50% methanol/PBT; 1x 5min 75% methanol/PBT; 2x 5min 100% methanol), 





2.5 Molecular biology 
2.5.1 RNA, protein and DNA extraction 
2.5.1.1 RNA extraction  
Total RNA from cultured cells was isolated using the RNeasy microkit or 
minikit (Qiagen), and performing on-column digestion with DNase I (Qiagen). 
 
2.5.1.2 RNA isolation with Trizol 
Protocol 
1. Lyse cells by adding 1ml of Trizol. Make sure to pipette the cell lysate 
several times to ensure proper homogenization.  
2. Incubate the homogenized samples for 5min at 15-30C to allow for 
complete dissociation of nucleoprotein complexes. 
3. Add 0.2ml of chloroform per 1ml of Trizol used. Shake simples vigorously 
by hand for 15sec and incubate them at 15-30C for 2-3min.  
4. Centrifuge the samples at no more than 12,000g for 15min at 2-8C (ALC 
PK120; Annita).  
5. Phase separation should be visible: (i) colourless upper aqueous phase 
(RNA), interphase (DNA) and lower phenol-chloroform phase (proteins and 
some DNA).  
6. Transfer the aqueous phase to a fresh tube.  
7. Precipitate the RNA from the aqueous phase by mixing with isopropyl 




centrifuge at no more than 12,000g for 10min at 2-8C (ALC PK120; Annita). 
The RNA is in the pellet. 
8. Remove the supernatant and wash the RNA pellet with 500l of 75% 
Ethanol. Mix the sample by vortexing and centrifuge at no more than 7,500g 
for 5min at 2-8C (ALC PK120; Annita).  
9. Resuspend the RNA pellet in 87l of RNAse free H20 and incubate at 56C 
for 10min.  
10. Add 3l of DNase I and 10l of RDD buffer. Incubate 10min at RT.  
11. Inactivate the DNAse I by incubating at 75C for 15min.  
12. Add 50l of phenol (pH 4.2) and 50l of chloroform.  Vortex the sample. 
13. Centrifuge the samples at no more than 12,000g for 15min at 2-8C (ALC 
PK120; Annita).  
14. Transfer the aqueous phase to a fresh tube with 10l NaOAc 3M pH 5,2. 
15. Add 300l of 100% ethanol. Incubate 2-4hrs at -80C or overnight at     -20C.  
16. Centrifuge the samples at no more than 12,000g for 10min at 2-8C (ALC 
PK120; Annita). 
17. Wash the RNA with 75% ethanol. 
18. Dissolve the RNA in 50l of RNAse free H20. Incubate at 56C for 10min.  
 
2.5.1.3 First strand cDNA synthesis 
Reverse transcription reactions were performed on 30 ng-2ug of total RNA 
in a final volume of 20µl with 100U of SuperScriptIII (Invitrogen) and 200ng random 






2.5.1.4 Real-time PCR 
Real-time RT–PCR reactions were performed in triplicate in 384-wells plates 
with a 480 LightCycler (Roche) using LightCycler 480 SYBR Green I Master (Roche). 
5µl of cDNA or immuno-precipitated chromatin were used per reaction. Standard 
curves of all primers were performed to check for efficient amplification, and all 
melting curves were generated to verify production of single DNA species with 
each primer pair. Values for each gene were normalised to expression of TATA box 






Table 2. 2 Primers used for qPCR 
Target Sequence 
TBP (sense) GGG GAG CTG TGA TGT GAA GT 
TBP (antisense) CCA GGA AAT AAT TCT GGC TCA 
Oct4 (sense) GTT GGA GAA GGT GGA ACC AA 
Oct4 (antisense) CTC CTT CTG CAG GGC TTT C 
Rex1 (sense) CAG CTC CTG CAC ACA GAA GA 
Rex1 (antisense) ACT GAT CCG CAA ACA CCT G 
FGF4 (sense) CCG GTT CTT CGT GGC TAT GA 
FGF4 (antisense) CTT ACT GAG GGC CAT GAA CAT 
Brachyury (sense) CAG CCC ACC TAC TGG CTC TA 
Brachyury (antisense) GAG CCT GGG GTG ATG GTA 
KLF4 (sense) GGC GAG AAA CCT TAC CAC TGT 
KLF4 (antisense) TAC TGA ACT CTC TCT CCT GGC A 
Sox2 (sense) GGC GGC AAC CAG AAG AAC AG 
Sox2 (antisense) GCT TGG CCT CGT CGA TGA AC 
FGF5 (sense) TTG CGA CCC AGG AGC TTA AT 
FGF5 (antisense) CTA CGC CTC TTT ATT GCA GC 
Hnf3B (Foxa2; sense) CAT CCG ACT GGA GCA GCT A 
Hnf3B (Foxa2; antisense) GCG CCC ACA TAG GAT GAC 
Esrrb (sense) TGG CAG GCA AGG ATG ACA GA 
Esrrb (antisense) TTT ACA TGA GGG CCG TGG GA 
Dppa3 (Stella; sense) GAT GCA CAA CGA TCC AGA TTT 
Dppa3 (Stella; antisense) TGG AAA TTA GAA CGT ACA TAC TCC AA 
KLF2 (sense) CTA AAG GCG CAT CTG CGT A 




2.5.1.5 Plasmid preparation from bacteria 
Overnight culture of DH5 bacterial cells containing the desired plasmid 
was performed in the appropriate drug selection. Next day, the plasmid DNA was 
isolated using Mini, Midi or Maxiprep kits (Qiagen). The final plasmid 
concentration was determined using a ND-1000 spectrophotometer. 
 
2.5.1.6 Ethanol precipitation 
Protocol 
1. Adjust pH of sample by adding sodium acetate (3M) to a final concentration 
of 0.2M. 
2. Add 2.5 volumes of ice cold ethanol (100%). 
3. Vortex the sample and then place at -20C for 30min. 
4. Microcentrifuge at max speed at 4C for 10min. 
5. Aspirate the ethanol. 
6. Wash pellet with 500l of ice cold ethanol (70%).  
7. Microcentrifuge at max speed at 4C for 5min. 
8. Aspirate the ethanol. 
9. Allow pellet to air dry for 5 min. 






2.5.2 DNA manipulation 
2.5.2.1 Restriction endonuclease digestion 
Plasmid DNA was digested enzymatically using restriction endonucleases 
from Roche and NEB. Enzymatic digestion was performed according to the 
manufacturer’s instructions.  
 
2.5.2.2 Ligation 
DNA ligations were performed using either T4 DNA ligase or Quick T4 
DNA Ligase (NEB). Ligations were set up with a 1:3 molar ratio excess of insert, 
using 50ng of vector. Ligations reactions were set up according to the 
manufacturer’s instructions.      
 
2.5.2.3 Agarose gel electrophoresis 
Preparation of 1% TBE gel 
200ml of 0.5x TBE buffer (1mM EDTA  + 45mM Tris-Borate) was mixed with 
2g of agarose (Cambrex). The mixture was heated in a microwave until the agarose 
was completely dissolved. 6l of ethidium bromide (10mg/ml) was added when the 
agarose had cooled below 60ºC and gels were poured into casting trays. 
Electrophoresis was performed in Mupid gel tanks at 25-130V in 0.5x TBE buffer. 1x 
DNA loading buffer with Ficoll (6x stock; Sigma) was used to label the DNA. 





2.5.2.4 Purification of digested DNA fragments 
Bands were purified from agarose gels by excision of the desired size using a 
clean scalpel blade on a trans-illuminator. Qiagen Gel Extraction Kit (Qiagen, 28704) 
was used for purification of nucleic acids according to the manufacturer’s 
instructions. 
 
2.5.2.5 Transformation of plasmid DNA into bacteria 
Luria Broth (LB) agar 
 Yeast extract (5%; Difco) 
 NaCl (5mM) 
 Agar (1.5%) 
 Tryptone (pancreatic digest of casein; 1%; Difco) 
Protocol 
1. LB agar was melted, cooled to below 60ºC and appropriate antibiotics 
added. 
2. LB agar (+antibiotics) was poured into plates. 
3. 50μL of competent DH5α (E. coli; Invitrogen) were thawed on ice. 
4. 10ng of plasmid DNA was then transformed into competent DH5α and 
incubated in ice for 30 minutes. 
5. The bacterial cells were then heat shocked for 30 seconds at 37C and then 
returned onto ice for 2 minutes. 
6. 950μl of LB added and tubes shaken at 37ºC for 1 hour on an orbital shaker. 





8. Plates were incubated overnight at 37ºC. 
 
2.5.2.6 Topo-cloning 
Cloning of blunt end PCR products were performed using the Zero Blunt 
TOPO cloning kit (Invitrogen). TOPO TA Cloning Kit (Invitrogen) was used for 
PCR products with a polyA overhang. Reactions were carried out according to the 
manufacturer’s instructions. Colonies formed on ampicillin plates were mini-
prepped and test digested with EcoR1 to check for insertion of the PCR product. 
PCR products were subsequently verified by DNA sequencing (School of Biological 
Sciences Sequencing Service, University of Edinburgh).  
  
2.5.3 Western Blotting 
2.5.3.1 Solutions and reagents 
Laemmli Lysis Buffer: 2% SDS, 10% Glycerol, 60mM Tris pH6.8, 0.1M DTT, 
Bromophenol blue 
 
Running Buffer:  NuPage MOPS, 20x (Invitrogen) 
 
Antioxidant:   NuPage Antioxidant (Invitrogen) 
 
Transfer Buffer:   20% MeOH, 25mM TRIS, 192mM Glycine, in dH2O 
 





Blocking Buffer: 10% dried, skimmed milk (Marvel), 0.05% NP40, in 
TBS 
 
Incubation Buffer:  5% dried, skimmed milk (Marvel), 0.15% NP40, in TBS 
 
Wash Buffer: 10mM TRIS, 650mM NaCl, 0.3% Triton x100, in dH2O, 
pH7.6-8.0 
 
Stripping Buffer:  2% SDS, 62.5mM TRIS, pH6.8 
 
Gels:    10% NuPage Bis-Tris (Invitrogen) 
12-14% NuPage Bis-Tris (Invitrogen) 
 
MW marker:    SeeBlue Plus2 (Invitrogen) 
 
Gel-tank:   Novex Mini-Cell (Invitrogen) 
 
Membrane:   Nitrocellulose (Hybond-ECL, Amersham) 
 
ECL:     ECL-plus (Amersham) 
 
2.5.3.2 Sample Preparation 
~2 x 106 cells were lysed directly on the wells of 6-well plates in 250μL 




samples were boiled for 5 minutes, sonicated briefly and subjected to SDS-PAGE 
directly or stored at -20C. 
 
2.5.3.3 Running the Gel 
10% or 12-14% Novex gels (Invitrogen) were used. The comb was removed, 
wells rinsed by pipetting running buffer into the wells and 20μL sample loaded per 




The gel was removed from its casing into transfer buffer, the foot and wells 
removed, and assembled with the membrane between 1 sponge and 2 sheets wet 
Wattman paper either side, taking care to avoid bubbles. The assembly was 
transferred at 395 amps for 70 minutes in a cold room in BioRad gel tanks. 
 
2.5.3.5 Blocking, antibody incubation, washing and stripping 
The membrane was placed protein side up in a 50ml tube and incubated for 
2hrs in blocking solution. Primary antibodies were diluted in 5ml (PBT/10% milk) 
and incubated with the membrane for 2hrs at RT or overnight at 4C. Secondary 
antibodies were diluted in PBT/10% milk and incubated with the membrane for 1hr 
at RT. Following primary and secondary antibody incubations membranes were 
washed 3 x 15 minutes in 30ml wash buffer. Membranes were incubated for 5 
minutes with ECL, exposed to X-ray film and developed. If membranes were to be 
re-probed antibodies were stripped by incubating for 30 minutes at 70C in 





Table 2. 3 Antibodies used for western blot 
Antibody Supplier Dilution 2º antibody 
Nanog Chambers, 2005 1:2000 Rabbit-HRP 
Oct4 (C10) Santa Cruz 1:1000 Mouse-HRP 
Sox2 (Y17) Santa Cruz 1:1000 Goat-HRP 
Esrrb Persaeus Proteomics 1:1000 Mouse-HRP 
HDAC Upstate 1:1000 Mouse-HRP 
 
2.7 Bisulphite genomic sequencing 
DNA was isolated using the DNeasy Blood & Tissue kit (Qiagen) and 
bisulphite-converted using the Imprint DNA modification kit (Sigma). The treated 
DNA was then PCR amplified using Platinum Taq DNA polymerase (Invitrogen) 
and the following Nanog promoter-specific primers: MeNanog-F2-S, GAT TTT GTA 
GGT GGG ATT AAT TGT GAA TTT and MeNanog-F2-AS, ACC AAA AAA ACC 
CAC ACT CAT ATC AAT ATA (Imamura et al., 2006). The cycling conditions were: 
940C for 10 min, followed by 40 cycles of 940C for 60s, 500C for 60s and 720C for 40s 
with a final 5 min extension at 720C. PCR products (367 bp amplicon) were gel-
purified and cloned into the pCRII-TOPO TA vector (invitrogen). Approximately 30 
clones were picked and sequenced with M13 forward and reverse primers. 






2.8 Formaldehyde-Assisted Isolation of Regulatory 
Elements (FAIRE) 
 Regions of active chromatin are characterized by their hypersensitivity to 
nucleases (Wu et al., 1979), which in turn correlate with nucleosomes-depleted 
regions (Boeger et al., 2003). Notably, the clearance of nucleosomes from active 
regulatory regions is a conserved mechanism in eukaryotes (Wallrath et al., 1994).  
Recently it has been shown that active promoters/transcription start sites are 
preferentially isolated using FAIRE (Giresi et al., 2007; Nagy et al., 2003).  
 
2.8.1 Preparation of embryos and cells 
FAIRE was performed as described (Giresi et al., 2007) with minor 
modifications. Embryos from MF1 inter-crosses were dissected and staged 
according to Downs and Davies classification as described above (Section 2.3.1). 
Each biological replicate consisted of 27-30 pooled E7.5 embryos or 20-22 E8.5 
embryos. Extra-embryonic tissue (including the allantois containing primordial 
germ cells) was removed from embryos, and the embryo proper was dissociated 
using 0.5% trypsin/2.5% pancreatin/PBS.  For MEFs or ES cells, 1x107 cells were 
used per replicate. For analysis of E8.5 explants, batches of 20-22 embryos were 
dissociated using 0.5% trypsin/2.5% pancreatin PBS and cells cultured in EpiSC 
conditions in the presence or absence of 1mg/ml Doxycycline. The next day, 
explants were dissociated with trypsin, replated on non-gelatinised tissue culture 





2.8.2 Chromatin preparation 
ES cells, MEFs or embryonic tissue was resuspended in 3ml of pre-warmed 
culture media (GMEM/FCS/LIF, GMEM/FCS and DMEM-
F12KOSR/Activin/bFGF respectively) and cross-linked for 10’ at RT with 1% 
formaldehyde (Sigma). The cross-linking reaction was stopped by adding 0.125mM 
glycine for 5 min at RT. Cells were pelleted (3 min, 1300rpm, 4°C) and washed twice 
with ice-cold PBS 1X (Invitrogen). Cell pellets were then vigorously resuspended in 
300µl of swelling buffer (5mM Pipes pH8, 85mM KCl) freshly supplemented with 
1X protease inhibitor cocktail (Roche) and 0.5% NP-40. After 20 minutes on ice with 
occasional shaking, nuclei were centrifuged  (1500rpm in 15ml conical tubes 
(Falcon-BD), 10 min, 4°C) and resuspended in 0.5ml (ES cells & MEFs) or 0.1ml 
(embryonic tissue) of TSE150 (0.1% SDS, 1% Triton, 2mM EDTA, 20mM Tris-HCl 
pH8, 150mM NaCl) buffer, freshly supplemented with 1X protease inhibitor 
cocktail. Samples were then sonicated at 4C (15ml conical tubes for cultured cells 
and 1.8ml microcentrifuge tubes for embryo-derived nuclei) using a Bioruptor 
(Diagenode) for 3-4 cycles of 10 min divided into 30 seconds ON-30 seconds OFF 
sub-cycles at maximum power.  Chromatin was then microcentrifuged for 30min at 
4°C (ALC PK120, Annita). Soluble chromatin was used immediately or stored at -
80C. Twenty microlitres were set apart and used to quantify the chromatin 
concentration and the size of the DNA fragments on a 1.5% agarose gel. 
 
2.8.3 Isolation of protein-free DNA fragments  
For isolation of nucleosome-depleted INPUT DNA, crosslinking was 




next day the following solutions were added, 5l of Proteinase K (20mg/ml), 5l 
glycogen (2g/ml) and 240l TE. The INPUT DNA was then placed at 37C for 
2hrs. The INPUT DNA was extracted with phenol-chloroform followed by ethanol 
precipitation and RNase A (100 μg/ml) treatment. Cross-linked samples were 
incubated at 65°C for 2hrs to ensure that no DNA–DNA crosslinks were maintained. 
Samples were amplified using a LightCycler 480 (Roche) and LightCycler 480 SYBR 






Table 2. 4 Primers used for FAIRE 
Target region Sequence 
Nanog (sense) TGG CCT TCA GAT AGG CTG AT 
Nanog (antisense) CAA GAA GTC AGA AGG AAG TGA GC 
Sox2 (Sense) AGG GCT GGG AGA AAG AAG AG 
Sox2 (antisense) CCG CGA TTG TTG TGA TTA GTT 
Oct4 (Distal Enhancer; sense) AGA GTG CTG TCT AGG CCT TA 
Oct4 (Distal Enhancer; antisense) CCA GAA CTC TCA ACC TCC CT 
Oct4 (Proximal Enhancer; sense) GGG AAG CAG GGT ATC TCC AT 
Oct4 (Proximal Enhancer; antisense) TCC CCT CAC ACA AGA CTT CC 
Tsix (sense) GCG CTT GCA GGT ACT TTT 
Tsix (antisense) AAG AGC CTT AGG TCC CGC C 
Actin (sense) CCG TTC CGA AAG TTG CCT T 











Several studies have shown that under self-renewal conditions, mouse ES 
cells exhibit considerable heterogeneity in the levels of factors such as Nanog, Stella, 
Rex and Pecam1 (Chambers et al., 2007; Furusawa et al., 2006; Hayashi et al., 2008; 
Toyooka et al., 2008). Nanog fluctuations in ES cells occur in the undifferentiated 
fraction of the population (Chambers et al., 2007). ES cells with low levels of Nanog 
show a pre-disposition towards differentiation, whereas high levels of Nanog 
present a bias towards self-renewal (Chambers et al., 2003; Chambers et al., 2007). 
Notably, different cellular substates within the undifferentiated compartment are 
reversible, thus, a cell that has low Nanog expression can give rise to a high Nanog 
expressing cell and vice versa (Chambers et al., 2007).  
 
In pre-implantation embryos FGF signaling is necessary for the specification 
of the lineages that make up the ICM (Arman et al., 1998; Cheng et al., 1998). FGF-
Erk signaling pathway has been reported to have an effect on the ability of cells to 




FGF4 transcription is directly activated in vitro by the synergistic interaction 
between Oct4 and Sox2 on the FGF4 enhancer (Dailey et al., 1994; Yuan et al., 1995). 
Oct4 expression in the ICM is not regionalized during the specification of the 
epiblast/hypoblast, whereas Sox2 and Nanog expression is restricted to the nascent 
epiblast (Guo et al., 2010). Therefore, it is conceivable that paracrine signaling, 
involving FGF4 secretion by epiblast cells, is crucial for the commitment of cells that 
express FGFr2 into primitive endoderm. In support of this hypothesis, when 8-cell 
embryos are cultured in the presence of inhibitors of the FGF/Erk pathway, the 
ICM of these embryos is composed exclusively of Nanog+ cells (Nichols et al., 2009). 
In summary, that the specification of the epiblast/hypoblast may involve a 
differential expression of FGF4 and FGFr2 in progenitor cells (Chazaud et al., 2006; 
Nichols and Smith, 2009; Yamanaka et al., 2010). It has also been suggested that 
paracrine FGF signaling in ES cells may play a role in priming cells for 
differentiation. Nanog plays a fundamental role in regulating ES cell self-renewal, 
therefore, it is likely that FGF signaling influences fate decisions through 
modulations of Nanog levels. However, the precise relationship between Nanog 
and FGF signaling remain poorly understood.  
 
Recent studies suggest that Nanog heterogeneity is influenced by the levels 
of Oct4 (Violetta Karwacki-Neisius, PhD thesis UoE). The level of Oct4 is a critical 
factor for the specification of fate in mouse ES cells. Normal diploid expression of 
Oct4 in ES cells is necessary to sustain self-renewal, a two fold increase in the levels 
of this transcription factor causes differentiation of a proportion of the population 
into primitive endoderm, while repression induces dedifferentiation into 




considerably less heterogeneous in Nanog expression than wildtype ES cells, with 
the vast majority of the undifferentiated population expressing high levels of Nanog 
(Violetta Karwacki-Neisius, PhD thesis UoE). Oct4+/- ES cells display a bias towards 
self-renewal, consistent with the high, homogenous Nanog expression. Importantly, 
the reduced Nanog heterogeneity observed in Oct4+/- can be manipulated to mimic 
the heterogeneity observed in wildtype ES cells by artificially increasing the Oct4 
levels (Violetta Karwacki-Neisius, PhD thesis UoE).  
 
The majority of the pluripotency-associated genes contain enhancers that 
possess Oct4/Sox2 binding motifs (Chen et al., 2008). Oct4 and Sox2 bind 
independently to their motifs, however, their binding to DNA is stabilized by 
protein-protein interaction in the ternary complex (Ambrosetti et al., 1997; 
Ambrosetti et al., 2000; Remenyi et al., 2003). Due to the close functional relationship 
between Oct4 and Sox2 it is feasible that the pluripotency network is susceptible to 
variation in Sox2 levels.  
 
3.2 Sox2 is essential for ES cell self-renewal 
Sox2 deletion in the embryo is lethal at the post-implantation stage. Detail 
analysis of Sox2-/- mutants reveals a role of Sox2 in the maintenance of the epiblast 
and extra-embryonic ectoderm, as the only surviving cells at this stage are giant 
trophoblast cells and extra-embryonic endoderm (Avilion et al., 2003). Sox2 
knockdown by siRNA in ES cells suggest that Sox2 is required to prevent ES cell 
differentiation into both the trophectoderm and epiblast-derived lineages (Ivanova 




Sox2 in ES cells results in differentiation of ES cells into trophectodermal cells, 
similar to Oct4 deletion (Masui et al., 2007). Interestingly, the phenotype observed 
following the genetic deletion of Sox2 could be rescued not only with ectopic Sox2, 
but also by an Oct4 transgene (Masui et al., 2007). Together these results suggest 
that Sox2 functions in ES cells to stabilize Oct4 expression. This has been 
hypothesized to occur by modulation of positive (Nr5a2) and negative (Nr2f2) 
regulators of the Oct4 (Masui et al., 2007). 
 
 To clarify the role of Sox2 in ES cell self-renewal, ES cell lines carrying 
mutations in the Sox2 gene were used (Sox2+/Bgeo and Sox2fl/Bgeo;Cre-ERT2 ES cells 
were a kind gift from Silvia Nicolis, University of Milano-Bicocca). Gene targeting 
was used to replace the Sox2 ORF with a fusion of -galactosidase and the 
neomycin-resistance gene (Figure 3.1A) (Zappone et al., 2000). The Sox2+/Bgeo ES cell 
line was further modified by the electroporation of a targeting vector containing a 
floxed-Sox2 sequence (Figure 3.1A) (Favaro et al., 2009). Finally, to achieve efficient 
conditional deletion of Sox2, a random integration of a CAG-driven Cre-ERT2 was 
performed (Figure 3.1A).  
 
Activation of the tamoxifen inducible Cre-recombinase in Sox2fl/Bgeo;Cre-ERT2 
(Sox2CKO) ES cells for 12h led to the complete loss of Sox2 protein (Figure 3.1B). 
Loss of Sox2 protein resulted in a marked reduction in the protein levels observed 








Figure 3. 1 Sox2 mutant ES cells 
 
(A) Strategy used for the construction of Sox2Bgeo/+ and Sox2CKO. Sox2 mutants 
were a kind gift from Silvia Nicolis.   
 
(B) Timecourse of Sox2 deletion in Sox2CKO ES cells. Western blot depicting the 





and Esrrb is observed 48h after the induction of Cre recombinase. Moreover, 
significant reduction of the Sox2 transcript can be detected as early as 3h after 
tamoxifen treatment (Figure 3.2). 
 
Oct4 and Nanog transcripts are reduced by 48h and become undetectable by 
72h after tamoxifen treatment (Figure 3.2). In the case of Esrrb, the transcript is 
reduced by 24h and becomes undetectable by 48h after tamoxifen treatment (Figure 
3.2). Klf4 transcript increases after 24h of the start of tamoxifen treatment until it is 
subsequently downregulated after 72h (Figure 3.3). Klf2 and Nr5a2 transcripts show 
a similar response to Sox2 deletion, displaying a progressive decrease in the level of 
the transcripts (Figure 3.3). The level of Tbx3 transcript is halved after 72h of 
tamoxifen treatment, decreasing even further by 96h (Figure 3.3).   
 
 To assess the role of Sox2 in ES cell self-renewal, Sox2CKO ES cells were 
seeded at clonal density in the presence or absence of tamoxifen. Sox2CKO ES cells 
cultured in FCS/LIF containing media, in the absence of tamoxifen treatment, 
yielded around 300 AP+ colonies after 7 days of culture (Figure 3.4). In contrast, a 
complete loss of AP+ colonies was observed after tamoxifen treatment for the 
duration of the assay (Figure 3.4). A shorter exposure to tamoxifen (30h) yielded a 
small number of AP+ colonies (~10). The deletion of Sox2 in a clonal assay was 
subsequently performed in N2B27/2i/LIF. Under such conditions, Sox2CKO ES 
cells seeded at clonal density, yielded around 600 AP+ colonies (Figure 3.4). 
Tamoxifen treatment for 30h significantly decreased the ability of Sox2CKO ES cells 










Figure 3. 2 Expression of pluripotency factors following Sox2 
deletion. 
 
Gene expression analysis of Sox2CKO following tamoxifen treatment with the 
indicated times. qPCR analyses were determined relative to TATA box-binding 
protein (TBP). All qPCR results are shown as the average of distinct experiments 













   
Figure 3. 3 Sox2 deletion leads to the downregulation of 
pluripotency associated factors.  
 
Gene expression analysis of Sox2CKO following tamoxifen treatment with the 
indicated times. qPCR analyses were determined relative to TATA box-binding 
protein (TBP). All qPCR results are shown as the average of distinct experiments 










Figure 3. 4 Effect of Sox2 deletion in ES cell self-renewal. 
 
Clonal assay of Sox2CKO ES cells. Sox2CKO were seeded at clonal density under 
different exposure periods to tamoxifen (top and middle panels) and in different 








Figure 3. 5 Rescue of Sox2CKO ES cells with exogenous Sox2. 
(A) Expression of Sox2, Nanog, Esrrb and Klf4 in Sox2CKO ES cells. Plasmids 
containing either empty vector, Sox2, Nanog, Esrrb or Klf4 were electroporated in 
Sox2CKO. Following electroporation the cells were seeded at a density of 1 x 106 
into a 100mm dish and selection was started. After 10 days, total mRNA was 
isolated from the populations. Error bars are the SD of 3 technical replicates.  
 
(B) Plasmids containing either empty vector, Sox2, Nanog, Esrrb or Klf4 were 
electroporated in Sox2CKO. Following electroporation the cells were seeded at a 
density of 1 x 106 into a 100mm dish. The following day, selection and tamoxifen 





tested whether Sox2 deficiency in ES cells could be rescued with other members of 
the pluripotency network (Figure 3.5). Although populations of ES cells 
overexpressing Sox2, Nanog, Esrrb or Klf4 could be generated (Figure 3.5A), only 
Sox2 was able to rescue the phenotype observed following Sox2 deletion in ES cells 
(Figure 3.5B). 
 
3.3 Sox2 is essential for EpiSC self-renewal 
Sox2CKO ES cells were differentiated in vitro into EpiSC by a medium 
switch from GMEM/FCS/LIF to N2B27/Activin/FGF. Sox2CKO EpiSC retained 
expression of the core pluripotency factors Oct4, Sox2 and Nanog, while 
upregulating the early marker for differentiation FGF5. Moreover, Sox2CKO 
downregulated the ES cell-specific factors Klf4, Klf2 and Esrrb (Figure 3.6). 
Sox2CKO cells also displayed bona fide EpiSC morphology in the absence of 
tamoxifen (Figure 3.7A). Interestingly, tamoxifen treatment of Sox2CKO EpiSC 
promoted differentiation and loss of self-renewal ability (Figure 3.7A). Protein 
analysis indicated that Sox2 protein is lost 48h after Cre-induction in Sox2CKO 






















Figure 3. 6Sox2CKO cells can make EpiSC.  
 
Marker expression analysis in Sox2CKO ES cells and EpiSC. qPCR analyses were 
determined relative to TATA box-binding protein (TBP). qPCR results are shown as 













Figure 3. 7 Sox2 deletion in Sox2KO EpiSC.  
 
(A) Brightfield images depicting the morphological changes occurring 48hrs after 
Sox2 deletion in EpiSC. 
 
(B) Western blot displaying the Sox2 protein level changes over 48h, following the 





3.4 Role of FGF and Sox2 on Nanog heterogeneity 
To study the effect of reduced Sox2 and Fgf signaling on Nanog expression, 
several ES cell lines were generated (Figure 3.8A). Sox2+/Bgeo (cells were a kind gift 
from Silvia Nicolis, University of Milano-Bicocca) and FGF4puro/Bgeo (Wilder et al., 
1997) ES cells were targeted with an eGFP at the Nanog AUG codon (Chambers et 
al., 2007). For each mutant ES cell lines 4 clones were analysed and representative 
results are displayed throughout the chapter 3. Staining for Oct4 protein in TNG 
and SONG ES cells showed that the undifferentiated fraction of the population 
displays a heterogeneous expression of Nanog:GFP (Figure 3.8B). Interestingly, the 
undifferentiated fraction (Oct4+ cells) of FNG ES cells displayed reduced 
heterogeneity in Nanog:GFP expression (Figure 3.8B).  
 
Quantitive PCR was used to compare the level of expression of several 
pluripotency associated transcription factors in TNG, SONG and FNG ES cells 
(Figure 3.9). Sox2 transcript was significantly lower in Sox2 heterozygous ES cells 
when compared to ES cells with intact Sox2 alleles (Figure 3.9). Consistent with 
these observations, the expression of the Sox2 target gene, Nr5a2, was significantly 
reduced in SONG (Figure 3.9). Interestingly, FGF4-/- ES cells a 2-fold increase in the 
level of Klf2 and Klf4 transcripts (Figure 3.9). FNG ES cells also displayed a modest 
increase in Nanog transcription (Figure 3.9). The Oct4 transcript levels in SONG and 










Figure 3. 8 Mutant ES lines to study Nanog heterogeneity. 
 
(A) Schemes showing the genetic modifications in TNG ES cells (Nanog+/GFP), 
SONG ES cells (Nanog+/GFP; Sox2+/Bgeo) and FNG ES cells (Nanog+/GFP; FGF4Puro/Bgeo). 
 






Figure 3. 9 Pluripotency gene expression in TNG, SONG and FNG 
ES cells.  
Pluripotency marker expression in TNG, SONG and FNG in the absence of selection 
for Nanog expression (Puromycin). qPCR analyses were determined relative to 
TATA box-binding protein (TBP). All qPCR results are shown as the average of 




TNG, SONG and FNG ES cells express Puromycin resistance from the Nanog locus, 
therefore drug selection allows for propagation of pure populations of Nanog+ ES 
cells (Figure 3.10). Pre-selected TNG, SONG and FNG ES cells were seeded at a low 
density in 6-well plates, without selection, in media containing FCS/LIF and in the 
presence or absence of recombinant basic FGF (bFGF). On the specified days the 
emerging populations were quantified for expression of SSEA-1 and Nanog:GFP 
using flow cytometry (Figure 3.10). Following two days of culture under these 
conditions, a small number of GFPlow cells began to emerge from the 
undifferentiated (SSEA-1+) fraction of TNG ES cells (Figure 3.10, top panels). A 
more pronounced shift in the proportion of GFPhigh/GFPlow in the undifferentiated 
fraction of the population was observed at day 4 (Figure 3.10, top panels). By day 7, 
a considerable proportion of the SSEA-1+ subpopulation had lost expression of 
Nanog:GFP (Figure 3.10, top panels). Supplementation of exogenous bFGF resulted 
in a modest increase in the number of GFPlow cells within the undifferentiated 
subpopulation (Figure 3.10, top panels). SONG ES cells displayed a broader 
Nanog:GFP distribution than TNG ES cells throughout the assay (Figure 3.10, 
middle panels). Moreover, SONG ES cells showed a faster appearance of GFPlow 
cells than TNG ES cells (Figure 3.10, middle panels). Similar to the observation 
made using TNG ES cells, supplementation of SONG ES cells with exogenous bFGF, 
had a modest effect on Nanog:GFP heterogeneity (Figure 3.10, middle panels). In 
stark contrast, FNG ES cells do not display an increase in the proportion of GFPlow 
cells (Figure 3.10, lower panels). Nanog:GFP expression in FNG ES cells remains 
homogenous for the duration of the assay (Figure 3.10, lower panels). Restoring FGF 





Figure 3. 10 Nanog:GFP expression in TNG, SONG and FNG ES 
cells. 
TNG, SONG and FNG ES cells, pre-selected for homogenous Nanog expression 
with Puromycin, were seeded in 6-well plates at low density. The following day, 
defined as day 0, selection was removed and the media was replaced with 
GMEM/FCS/LIF in the presence or absence of bFGF. Cells were then stained for 
SSEA-1 and analysed by flow cytometry on days 0, 2, 4 and 7. Representative FACS 
plots are shown. At least 4 biological replicates were performed for each FACS 




appearance of SSEA-1+/GFPlow cells between days 2-4 of treatment (Figure 3.10, 
lower panels). 
 
In flow cytometry, two measures are generally taken from a fluorescent 
distribution, intensity and spread. The intensity of a distribution can be represented  
arithmetically by the mean or median. If the data has been displayed on a 
logarithmic scale, the geometric mean is preferred ((Shapiro, 2003) Figure 3.1A). The 
spread of a distribution is usually displayed as the Standard Deviation (SD). 
However, the coefficient of variation (CV) is a useful alternative as takes into 
account the biological variation and the measuring variation (CV = SD/mean). The 
CV is a function that allows the quantitative comparison of the heterogeneity 
observed in a fluorescent distribution.  
 
TNG, SONG and FNG ES cells were seeded at low density in 
GMEM/FCS/LIF alone or supplemented with either a GSK3 (CHIR99021) or MEK 
(PD0325901) inhibitor. Each day the levels of Nanog:GFP were measured using flow 
cytometry. The CV and median were calculated for each sample and the average of 
four biological repeats were plotted (Figure 3.11). Upon release from selection, 
Nanog:GFPlow cells were readily generated in cultures of TNG ES cells at low density 
in GMEM/FCS/LIF (Figure 3.10) (Chambers et al., 2007). As expected, the CV of 
Nanog:GFP in TNG ES cells showed a consistent increase for the duration of the 
experiment (Figure 3.11A, left panel). Culture of TNG ES cells in GMEM/FCS/LIF 
supplemented with a GSK3 inhibitor reduced significantly the increase in the CV of 








Figure 3. 11 Changes in Nanog heterogeneity following MEK and 
GSK3 modulation in TNG, SONG and FNG ES cells.  
 
(A) CV and median analysis of Nanog:GFP in TNG cells following MEK 
(PD0325901) and GSK3 (CHIR99021) modulation.  
 
(B) CV and median analysis of Nanog:GFP in SONG cells following MEK 
(PD0325901) and GSK3 (CHIR99021) modulation. 
 
(C) CV and median analysis of Nanog:GFP in FNG cells following MEK (PD0325901) 






Strikingly, the CV of Nanog:GFP from TNG ES cells  cultured in GMEM/FCS/LIF 
supplemented with a MEK inhibitor (PD0325901) showed a consistent decrease 
(Figure 3.11A, left panel). Furthermore, culture of TNG ES cells at low density in 
GMEM/FCS/LIF alone or supplemented with a GSK3 inhibitor (CHIR99021) 
resulted in a progressive decrease in the median of Nanog:GFP (Figure 3.11A, right 
panel). Exposure of TNG ES cells to the MEK inhibitor (PD0325901) in the presence 
of serum containing medium resulted in an increase in Nanog:GFP (Figure 3.11, 
right panel). 
 
Similar to TNG cells, SONG ES cells readily generated Nanog:GFPlow cells 
when seeded at low density in GMEM/FCS/LIF (Figure 3.10). SONG ES cells also 
displayed a growth in the CV of Nanog:GFP under similar conditions (Figure 3.11B, 
left panel). Inhibition of either GSK3 (CHIR99021) or MEK (PD0325901) prevented 
an increase in heterogeneity of Nanog:GFP in SONG ES cells (Figure 3.11B, left 
panel). The overall levels of Nanog:GFP showed a gradual decrease with time when 
SONG ES cells were plated at low density in GMEM/FCS/LIF alone or 
supplemented with a GSK3 inhibitor (Figure 3.11B, right panel). In contrast, SONG 
ES cells grown in the presence of a MEK inhibitor (PD0325901) showed an overall 
increase in the median of Nanog:GFP (Figure 3.11B, right panel).  
 
ES cells lacking a functional copy of the FGF4 gene failed to generate the 
Nanog:GFPlow cells at the same rate as controls ES cell lines (Figure 3.10). Restoring 







Figure 3. 12 Effect of GSK3 and MEK inhibition on the CV and 
median of Oct4:GFP.  
 
(A) Changes in CV of Oct4:GFP in Oct4GiP ES cells after removal of selection. 
 
(B) Observed changes in the median of Oct4:GFP in Oct4GiP ES cells after removal 





cells to generate undifferentiated Nanog:GFPlow cells (Figure 3.10; Figure 3.11C, left 
panel). Culture of FNG ES cells at low density in GMEM/FCS/LIF alone or 
supplemented with a PD0325901 failed to display a significant change in the CV of 
Nanog:GFP (Figure 3.11C, left panel). On the other hand, FNG ES cells grown in 
GMEM/FCS/LIF supplemented with either a GSK3 inhibitor or bFGF showed a 
consistent increase in the CV of Nanog:GFP (Figure 3.11C, left panel). Propagation of 
FNG ES cells at low density in GMEM/FCS/LIF supplemented with bFGF 
promoted a progressive decrease in the median of Nanog:GFP (Figure 3.11C, right  
panel). FNG ES cells cultured in GMEM/FCS/LIF alone or in the presence of 
either a GSK3 (CHIR99021) or MEK (PD0325901) inhibitor did not show a 
significant change in the median of Nanog:GFP (Figure 3.11C, right panel).  
 
Oct4 levels are critical in the specification of fate in mouse ES cells (Niwa et 
al., 2000). Moreover, reduced Oct4 levels (~50%) promote homogenous Nanog 
expression and robust pluripotency (Violetta Karwacki-Neisius, PhD thesis UoE). 
Therefore, it is of interest to determine the expression dynamics of Oct4 in self-
renewing ES cells. In order to achieve this, ES cells that contain a GFP transgene 
driven by the entire regulatory region of Oct4 (Yeom et al., 1996) were analysed 
using a similar experimental setup (Figure 3.12). Oct4GiP ES cells cultured at low 
density in GMEM/FCS/LIF alone or supplemented with a MEK inhibitor 
(PD0325901) showed a moderate change in the CV of Oct4:GFP (Figure 3.12A). 
Notably, GSK3 inhibition (CHIR99021) in Oct4GiP ES cells promotes a reduction in 
the CV of Oct4:GFP (Figure 3.12A). Under all culture conditions tested, the median 





  Interestingly, SONG ES cells show a broader dispersion of Nanog:GFP when 
compared to TNG and FNG ES cells (Figure 3.10). Moreover, SONG ES cells 
displayed a higher CV of Nanog:GFP than TNG and FNG ES cells cultured in 
GMEM/FCS/LIF (Figure 3.11; 3.13A). Culture of TNG and SONG ES cells in the 
combined presence of CHIR99021 and PD0325901 significantly reduced the CV of 
Nanog:GFP (Figure 3.11A, B). Dual inhibition of GSK3 (CHIR99021)/MEK 
(PD0325901) in FNG ES cells did not have a significant effect on the CV of 
Nanog:GFP (Figure 3.13A). Strikingly, the CV of Nanog:GFP in TNG, SONG and 
FNG is comparable when the cells are cultured in the presence of N2B27/2i/LIF 
(Figure 3.13A). Propagation of Oct4GiP ES cells in 2i resulted in a moderate 
decrease in the CV of Oct4:GFP (Figure 3.13A). The median of Nanog:GFP was 
higher in FNG ES cells when compared to TNG and SONG ES cells (Figure 3.13B). 
Nanog:GFP levels were augmented in TNG and SONG ES cells by dual inhibition of 
GSK3 (CHIR99021)/MEK (PD0325901) (Figure 3.13B). Conversely, Oct4 levels are 
lower in cells cultured in the presence of GSK3 (CHIR99021) and MEK (PD0325901) 










Figure 3. 13 Effect of combined Gsk3 and MEK inhibition on 
Nanog:GFP and Oct4:GFP in different mutant ES cells lines.  
 
(A) CV comparison of Nanog:GFP and Oct4:GFP in mutant ES cells cultured in 
FCS/LIF and 2i/LIF.  
 
(B) Differences in the median of Nanog:GFP and Oct4:GFP in mutant ES cells 






Mouse ES cells are routinely cultured in GMEM/FCS/LIF (Smith, 1991). 
Although this culture condition promotes robust self-renewal of ES cells, 
differentiation is not completely abolished. Culturing ES cells in the above medium 
promotes the propagation of a heterogeneous population. Pluripotent transcription 
factors such as Nanog are heterogeneously expressed (Chambers et al., 2007). 
Moreover, lineage specific genes are expressed at low levels, a phenomenon termed 
as lineage priming (Hu et al., 1997; Mikkelsen et al., 2007). In this chapter the role of 
FGF signaling and Sox2 levels on heterogeneous Nanog expression in mouse ES 
cells is examined.    
 
3.5.1 The role of Sox2 in ES cell self-renewal and Nanog 
heterogeneity 
Sox2Bgeo/+ and Sox2Bgeo/flx:CreERT2 mutant ES cells were used to study the 
effect of Sox2 levels on ES cell self-renewal and Nanog heterogeneity. Firstly, Sox2 
mutant ES cells were characterized. Consistent with a previous report (Masui et al., 
2007), deletion of the loxP-flanked Sox2 allele from Sox2Bgeo/flx:CreERT2 ES cells 
induced differentiation (see Section 3.2). Biochemical analysis of Sox2Bgeo/flx:CreERT2 
ES cells following tamoxifen treatment showed disappearance of Sox2 mRNA 
within 3h, whereas the protein was downregulated between 9-12h (see Section 3.2). 
This suggests that in undifferentiated ES cells Sox2 is intrinsically a stable protein, 
increasing the likelihood that Sox2 may be significantly regulated at the protein 
level. Additionally, one could predict that in response to differentiation cues, the 




for at least 24h after Cre-mediated deletion of Sox2, changes in the expression of 
Nr5a2, Klf2, Esrrb and Nanog can be detected at earlier time points (see Section 3.2). 
This suggests that Sox2 may have other functions in ES cells than simply stabilizing 
Oct4 expression as has been proposed (Masui et al., 2007). Future work will be 
critical to identify Sox2 target genes that are particularly susceptible to changes in 
Sox2 levels and their effect on pluripotency and ES cell self-renewal. Interestingly, 
changes in Oct4 protein are apparent prior to transcriptional modulation of Oct4 
after genetic deletion of Sox2 (see section 3.2). This could be an indication that Sox2 
may regulate the stability of Oct4 protein, In this regard, Sox2-/- ES cells rescued 
with a mutant forms of Oct4 may provide useful a tool to further characterize the 
Oct4-Sox2 interaction.  
  
In post-implantation embryos Sox2 is expressed in the epiblast and extra-
embryonic ectoderm, while, at the onset of gastrulation, it becomes restricted to the 
prospective neural plate and chorion (Wood and Episkopou, 1999). Despite the 
expression pattern of Sox2 being well documented, its function in the post-
implantation epiblast remains poorly characterized. Nonetheless, it is essential as 
Sox2 deletion in EpiSCs induces overt differentiation into mesenchymal-like cells 
(see Section 3.3). One possible role for Sox2 in the post-implantation epiblast is to 
promote the expression of Oct4, as has been suggested to occur in ES cells. The 
mechanism through which this would be achieved is not clear. It has been 
suggested that the induction of Oct4 expression may occur through the Sox2 target 
gene, Nr5a2. Indeed, Nr5a2 has been shown to bind to Oct4 proximal promoter and 
proximal enhancer (Gu et al., 2005). Moreover, Nr5a2 deficient embryos displayed 




2005). However, chimaeras produced by tetraploid aggregation of Nr5a2-/- cells 
were able to develop through gastrulation, suggesting that the loss of Oct4 
expression in the epiblast is likely to be the result of the defective formation of the 
visceral endoderm (Labelle-Dumais et al., 2006). Furthermore, Nr5a2 can be deleted 
from ES cells without an apparent effect on self-renewal (Gu et al., 2005). 
Additionally, Oct4 is abundant in EpiSC, whereas the Nr5a nuclear receptors are not 
expressed (see Chapter 5; (Guo and Smith, 2010)). Therefore, Nr5a2 is not essential 
for the expression of Oct4 in the epiblast or in its in vitro derivatives. Further 
characterization is necessary to determine the mechanism through which Sox2 
promotes Oct4 expression and additional functions that Sox2 may have in 
pluripotent cells.  
 
Recent work has shown that changes in Oct4 levels have a profound effect 
on ES cell self-renewal. Oct4 heterozygote ES cells are considerably less 
heterogeneous in Nanog expression than wildtype ES cells. Consistent with 
previous results, these cells show a bias towards self-renewal and less readily 
differentiate (Violetta Karwacki-Neisius, PhD thesis UoE). Furthermore, it has been 
shown that Oct4 and Sox2 bind their motifs independently (Ambrosetti et al., 1997; 
Ambrosetti et al., 2000), however, their binding to DNA is stabilized by protein-
protein interaction in the ternary complex (Remenyi et al., 2003). Due to the close 
functional relationship between Oct4 and Sox2 it is feasible that the pluripotency 
network is susceptible to variations in Sox2 levels.  Sox2Bgeo/+ ES cells were used to 
study the effect of lower Sox2 levels on Nanog heterogeneity. A Nanog reporter line 
was made by introducing eGFP at the Nanog AUG codon of Sox2Bgeo/+ ES cells 




(SONG) displayed greater heterogeneity for Nanog expression than cells with wild-
type Sox2 levels (see Section 3.4). It is important to mention that the observed 
variation in Nanog levels were not the result of spontaneous differentiation, but 
rather occurred in the undifferentiated (Oct4+/SSEA-1+) fraction of SONG ES cells. 
This would be consistent with a strictly positive role for Sox2 on Nanog expression, 
either through the proximal Oct4/Sox2 site (Kuroda et al., 2005; Rodda et al., 2005) 
or through binding to the -5kb regulatory element (Loh et al., 2006). Moreover, 
lower Sox2 levels have been shown to be permissive for hES cell and EpiSC self-
renewal (Han et al., 2010; Osorno et al., 2012; Wang et al., 2012). As EpiSCs display 
lower Sox2 levels when compared to ES cells, it would be interesting to determine 
whether, similar to Nanog, Sox2 downregulation is required to allow the transition 
from naïve to primed pluripotency. In support of this hypothesis, it has been shown 
that Sox2 knockdown leads to upregulation of epiblast and trophectodermal 
markers (Ivanova et al., 2006). The effect of lower Sox2 levels on Nanog 
heterogeneity contrasts markedly to those observed for Oct4+/- ES cells (see Section 
3.4; Violetta Karwacki-Neisius, PhD thesis UoE), suggesting that changes in Oct4 
levels have a blatant effect on the expression of pluripotency network components, 
whereas variation in Sox2 levels may have more subtle effects. Future studies will 
be required to reveal the precise function of the Sox2/Oct4 and Sox2/Nanog 
interactions in the context of the GRN of pluripotent cells.  
 
Intriguing is the observation that MEK (PD0325901) and GSK3 (CHIR99021) 
inhibition in Sox2Bgeo/+ ES cells greatly reduces Nanog heterogeneity (see Section 
3.4). This suggests that changes in the pluripotency network induced by reduction 




been reported that Sox2 knockdown in ES cells results in ERK1/2 hyper-
phosphorylation (Ivanova et al., 2006), suggesting that Sox2 may be necessary to 
moderate MEK/ERK activation in ES cells. In summary, changes in Sox2 levels have 
a more modest effect on Nanog heterogeneity than variation of Oct4 levels. Further 
studies are necessary to determine whether ES cells with reduced Sox2 levels show 
hyper-activation of ERK1/2 and GSK3, supporting the role of Sox2 in the 
stabilization of naïve pluripotency. 
 
3.5.2 Role of FGF signaling on Nanog heterogeneity 
There is a growing body of information strongly supporting the relation 
between FGF/MEK/ERK signaling pathway and the promotion of differentiation 
(Burdon et al., 1999; Kunath et al., 2007; Stavridis et al., 2007). Moreover, in vivo 
studies demonstrating that FGF/MEK/ERK activity is essential for the formation of 
the lineages present in the ICM provides confidence that such pathway is not an 
artefact of the in vitro model (Chazaud et al., 2006; Nichols et al., 2009; Yamanaka et 
al., 2010). As a result, the observation that inhibition of FGF/MEK/ERK pathway in 
vivo promotes bias toward the formation of Nanoghigh cells (Nichols et al., 2009) is 
relevant in the context of ES cell biology.  
 
 In order to study the role of FGF signaling on Nanog expression, a reporter 
line was made by introducing eGFP into the Nanog AUG codon of FGF4-/- ES cells 
(FNG). Side-by-side experiment using FNG and TNG ES cells clearly showed that 
FGF4-/- ES cells are less heterogeneous for Nanog than ES cells with a functional 




capacity of FNG ES cells by re-instating heterogeneous Nanog expression. However, 
ES cells with functional FGF4 did not display increased differentiation upon 
addition of exogenous bFGF, further supporting the notion that FGF signaling in ES 
cells is necessary to prime the cells for differentiation. Interestingly, addition of 
exogenous FGF to wildtype ES cells did not produce a significant increase in Nanog 
heterogeneity, suggesting that FGF signaling may have a saturation point. One can 
predict that basal FGF activation may be necessary to promote early differentiation 
events, inducing lineage priming, but the pathway saturates promptly preventing it 
from acting in the final stages of differentiation. Alternatively, it is possible that FGF 
signaling is required to generate a balanced Nanoghigh/Nanoglow population, with 






The developmental loss of somatic 
pluripotency is reversed by ectopic Oct4 
 
4.1 Introduction 
 The original studies that proved that the embryo proper contained 
pluripotent cells were done by testing their ability to form teratocarcinoma (Solter et 
al., 1970; Stevens, 1968, 1970). Subsequent analysis showed that the cellular origin of 
the teratocarcinoma forming potential was the epiblast (Diwan and Stevens, 1976). 
The pluripotent epiblast first appears in the ICM of mouse blastocysts. After 
implantation the epiblast undergoes dramatic expansion and morphogenesis, 
resulting in the transformation of the epiblast from an unstructured cell mass into a 
columnar epithelium.  
 
Previous analyses have demonstrated that somatic pluripotency is lost in the 
mouse at some point between E7.5 and E8.5 (Damjanov et al., 1971). Moreover, 
pluripotent stem cells have been derived from the epiblast layer of post-
implantation mouse embryos from E5.5-6.5 (Bao et al., 2009; Brons et al., 2007; 
Greber et al., 2010; Tesar et al., 2007). It is well documented that pluripotency in pre-
implantation embryos and ES cells is governed by a gene regulatory network 




Chambers et al., 2007; Masui et al., 2007; Mitsui et al., 2003; Nichols et al., 1998; 
Niwa et al., 2000; Silva et al., 2009). Notably, these factors are also expressed in the 
post-implantation epiblast and its in vitro derivative EpiSC (Avilion et al., 2003; 
Brons et al., 2007; Downs, 2008; Hart et al., 2004; Scholer et al., 1990a; Tesar et al., 
2007; Wood and Episkopou, 1999; Yeom et al., 1996). Interestingly, the expression of 
Nanog, Oct4 and Sox2 in post-implantation embryos does not precisely match the 
reported presence of pluripotent cells. Indeed, Sox2 is expressed in the 
neurectoderm beyond the onset of somitogenesis (Avilion et al., 2003; Wood and 
Episkopou, 1999). Oct4 can be detected in somatic cells until about ~E8.5, thereafter 
it becomes restricted to the primordial germ cells (Downs, 2008; Scholer et al., 1990a; 
Scholer et al., 1990b; Yeom et al., 1996). Nanog disappears from somatic cells at 
some point between E7.5-8.5 (Hart et al., 2004; Hatano et al., 2005). It is therefore of 
considerable interest to determine the expression of these key factors in the post-
implantation embryos, and define their role in the maintenance of primed 
pluripotency.  
  
4.2 Pluripotency disappears from the epiblast as Oct4 
and Nanog levels decline 
The expression of Oct4, Sox2 and Nanog in the post-implantation embryo 
was analysed. Immunofluorescence, in situ hybridization and GFP reporter 
expression from the endogenous Nanog gene, indicate that from the start of 






Figure 4. 1 Expression of Nanog mRNA, protein and Nanog:GFP in 
post-implantation embryos. 
(A) Whole-mount in situ hybridization in ES to EHF embryos for Nanog. Pre-
somitogenesis embryos were staged according to Downs and Davies classification 
(Downs and Davies, 1993). Older embryos were staged by number of somite pairs. 
Asterisk, primitive streak in transverse section of EHF stage embryo showing cells 
downregulating Nanog mRNA as they ingress into the primitive streak. ES, early 
streak; MS, mid-streak; LS, late streak; OB, no allantoic bud; EHF, early headfold; 
LHF, late headfold.  
 
(B) NANOG localisation in a MS stage embryo. Arrow, distal-anterior region 
lacking Nanog expression. 
 
(C) Nanog:GFP localisation in ES to 2-3s stage embryos. Arrowheads, PGCs 
expressing Nanog:GFP. 
 
(D) Wholemount in situ hybridization for Oct4 in 5-6s stage embryo. Left: whole 
embryo. Right: transverse sections showing expression in PGCs(1) and somatic 
tissue (2-4). 
 
(E) Wholemount in situ hybridization for Oct4 in 15-17s stage embryo showing 





undetectable in the distal-anterior epiblast (Figure 4.1A-C). It was also observed that 
cells downregulate Nanog mRNA as they ingress into the primitive streak (Figure 
4.1A). Nanog disappears completely from the epiblast at the onset of somitogenesis, 
and is thereafter expressed exclusively in the germ line (Figure 4.1A-C). On the 
other hand, Oct4 is expressed in the entire epiblast until the late bud stage and its 
expression persists in somatic cells until about 12-15 somite (s) embryos (Figure 
4.1D-E) (Downs, 2008; Scholer et al., 1990a; Yeom et al., 1996). After ~12-15s stage, 
Oct4 is exclusively expressed in the germ line (Figure 4.1E). Quantitive RT-PCR 
(qPCR) was used to analyse the expression of the core pluripotency transcription 
factors during the time window in which somatic pluripotency disappears 
(Damjanov et al., 1971)). Sox2 expression gradually increases, while Nanog and Oct4 
decline between E7.5-E8.5, eventually becoming undetectable at 3-5s and 12 15s 
respectively (Figure 4.2A). 
 
4.3 Pluripotency disappears at the onset of 
somitogenesis and is equivalent in Nanog-negative and 
Nanog-positive epiblast 
Given the observation that Nanog expression showed the closest correlation 
with pluripotent cells in implantation embryos, the potency of Nanog expressing 
and non-expressing cells was tested. The last detectable expression of Nanog:GFP in 
somatic cells is the distal tip at 0-1s (Figure 4.2B). Furthermore, the distal region of 
2-5s retained Oct4 expression (Figure 4.3A). Indeed, qPCR analysis of the distal tip 







Figure 4. 2 Oct4 and Nanog levels decline shortly after the onset 
of somitogenesis. 
 
(A) qPCR analysis of Oct4, Nanog and Sox2 mRNAs in pooled embryos. Error bars: 
s.e.m. of 3 biological replicates. mRNA preparations and qPCRs were performed by 
Dr. Anestis Tsakiridis. 
 
(B) Nanog mRNA and Nanog:GFP expression. Arrow, distal-anterior region lacking 






Figure 4. 3 Pluripotency disappears from the epiblast as Oct4 and 
Nanog levels decline. 
(A) Sagittal section of a 2-3s stage embryo analysed by in situ hybridization for Oct4. 
 
(B) qPCR of distal region in 2-5s embryos for Nanog, Oct4 and Sox2. Values 
normalized to TBP and expressed relative to ES cell levels. 
 
(C) Teratocarcinoma-forming capacity of distal regions of pre-somite and 
somitogenesis stage embryos (boxes).   
 
(D) Ability of E7.5-8.25 embryos to form EpiSC. Top: EpiSC colony morphology. 
Middle: Expression of Nanog:GFP. Bottom: Immunoreactivity to Nanog and Oct4. 
pluripotency disappears at early somitogenesis, coincident with extinction of Nanog 




transcripts were absent (Figure 4.3B). Therefore, the distal region of headfold and 2-
5s embryos was tested for pluripotency (Figure 4.3C-D). Consistent with published 
data, kidney capsule grafts of headfold stage embryos produced large 
teratocarcinomas (Figure 4.3C) (Beddington, 1983). Conversely, similar tissue from 
2-5s embryos produced small growths devoid of EC cells and endoderm (Figure 
4.3C).  
 
Next, the concordance of EpiSC derivation and teratocarcinoma formation 
was tested. EpiSC lines have previously been derived from E5.5-6.5 (Bao et al., 2009; 
Brons et al., 2007; Greber et al., 2010; Tesar et al., 2007). Given the observation that 
Oct4, Sox2 and Nanog are expressed in headfold stage embryos their ability to 
generate EpiSC was tested. Upon explantation of tissue from E7.5-E8.0 embryos 
onto EpiSC culture conditions, Nanog:GFP was readily detected in explants (Figure 
4.3D). These explants could be passaged and in all cases (8/8) gave rise to EpiSC 
lines that expressed Oct4 and Nanog protein (Figure 4.3D). In contrast, explants 
from 2-4s embryos did not express Nanog:GFP (0/6). Upon passaging, these 
explants produced morphologically differentiated cells that did not express Oct4 or 
Nanog (Figure 4.3D). Thus, EpiSC derivation ability is an effective assay to test the 
presence of primed pluripotency in post-implantation embryos.  
 
To examine the relationship between pluripotency and Nanog expression in 
more detail, a staged series of Nanog:GFP embryos was isolated, separated into  
Nanog-nonexpressing (distal/anterior) and Nanog-expressing (proximal/posterior) 












Figure 4. 4 Pluripotency disappears at the onset of somitogenesis 
and is equivalent in Nanog-negative and Nanog-positive epiblast. 
 
(A) E7.5 embryos expressing Nanog:GFP were dissected along the indicated lines 
into anterior (A) and posterior (P) fragments. Bottom; Nanog:GFP expression upon 
explantation onto feeders and DMEM-F12  
 
(B) Embryos before micro-dissection, arranged from oldest (left) to youngest (right).  
 
(C) Immuno-histochemical detection of Oct4 and Nanog in representative colonies 
of EpiSC lines derived from these embryos. A1-5 and P1-5 correspond to lines 










bright Nanog:GFP+ cells at the base of the allantois allowed us to confirm exclusion 
of these cells from posterior explants. Without exception, prior to somitogenesis, 
anterior and posterior explants showed Nanog expression at 24-48 hours (Figure 
4.4A) and primary explants displayed robust Oct4 and Nanog expression (Figure 
4.4B-C). Moreover, EpiSC lines were readily derived from anterior and posterior 
regions of pre-somitogenesis embryos (n=12 for each; Figure 4.5A-B). Interestingly, 
explants from somitogenesis stage embryos failed to reactivate Nanog expression 
and did not generate EpiSC lines (0/23; Figure 4.3D; Figure 4.4B-C). Additionally, 
the potency of Nanog-nonexpressing (distal/anterior) and Nanog-expressing 
(proximal/posterior) regions was assessed using kidney capsule grafts. Notably, 
anterior and posterior regions showed equivalent teratocarcinoma-forming capacity 
(Figure 4.6). In summary, somatic pluripotency disappears between headfold and 
somitogenesis stages. Moreover, prior to somitogenesis, Nanog-expressing and 
Nanog-nonexpressing regions remain pluripotent. However, the observation that 
Nanog is re-expressed in anterior explants within 24 hours of culture in EpiSC 












Figure 4. 5 Nanog-negative and Nanog-positive epiblast regions 
readily make EpiSC. 
 
(A) qPCR analysis of representative anterior and posterior E7.5 EpiSC lines. ES cells 
and E6.5 EpiSC were used as controls. ES cell/EpiSC markers are common to both 
ES and EpiSC lines. 
 
(B) Nanog and Sox2 immunofluorescence in representative anterior and posterior 




















Figure 4. 6 Anterior and posterior epiblast at E7.5 are pluripotent. 
 
(A) Nanog:GFP embryos were dissected into Nanog:GFP+ (posterior) and 
Nanog:GFP- (anterior) regions (as depicted in Figure 4.3A). The extra-embryonic 
region was removed, as well as the most proximal epiblast containing the PGCs. 
The embryonic fragments were checked with fluorescence optics to verify the 
accuracy of the dissection. Kidney capsule grafts were performed as described 
previously (Tam, 1990). The number of teratocarcinomas in anterior and posterior 
regions is depicted as a fraction of total tumours (n, number of grafts performed).  
 
(B) Anterior/posterior-derived tumour composition. Grafts shown in (A) were 
scored for germ layer differentiation. The presence or absence of EC cells and germ 







4.4 Nanog is not required for post-implantation 
pluripotency 
At least two possibilities may explain the observation that Nanog-
nonexpressing epiblast cells are pluripotent: (1) these cells represent a latent 
pluripotent state that requires Nanog reactivation to manifest pluripotency, or (2) 
Nanog is not essential for epiblast pluripotency. In order to distinguish between 
these possibilities, ES cells genetically depleted for Nanog were used to produce 
E6.5-E7.5 chimaeras, which were then tested for their ability to generate EpiSCs 
(Figure 4.7). Two Nanog–/– cell lines TC44cre6 and RCNH-B(t), alongside a control 
derivative line RCNH-B(t)R, in which one of the non-functional Nanog alleles has 
been repaired by homologous recombination, were used for these experiments  
(Chambers et al., 2007). Discrimination of wild-type and ES-derived cells is possible 
because RCNH-B(t) and RCNH-B(t)R express GFP constitutively, whereas 
TC44cre6 expresses GFP from a targeted Nanog-null allele. Nanog–/– cells formed 
chimaeras indistinguishable from wild-type or Nanog–/+ cells (Figure 4.7B). Primary 
explants from Nanog–/– chimaeras were picked and expanded to produce two 
independent EpiSC lines that lacked Nanog, but showed robust Oct4 and Sox2 
expression (Figure 4.7B). To exclude the formal possibility that derivation or 
survival of chimaera-derived Nanog-null EpiSC required co-culture with wild-type 
cells, pure Nanog–/– ES cell populations were differentiated in vitro into EpiSC (Guo 
et al., 2009). Two independent in vitro derived Nanog–/– EpiSC lines were readily 
obtained (Figure 4.8). In vitro derived TC44cre6 and RCNH-B(t) displayed robust 
Oct4 and Sox2 expression (Figure 4.8A). Furthermore, the two in vitro derived 





Figure 4. 7 Nanog is dispensable for the derivation and 
maintenance embryo-derived EpiSC. 
 
(A) Experimental strategies for derivation and analysis of Nanog-/- EpiSC lines used 
throughout the chapter.  
 
(B) Top: chimeric embryos with Nanog mutant cells expressing constitutive GFP. 
Below: Oct4, Sox2 and Nanog immunofluorescence in established EpiSC lines from 
chimeric embryos. Nanog-/- RCNH-B(t) EpiSC line was analysed alongside the 




Nanog–/– EpiSCs, alongside a control Nanog+/+ EpiSCs, were grafted into the kidney 
capsule of mice. Remarkably, similar to control Nanog+/+ EpiSC, Nanog-/- EpiSC 
produced teratocarcinomas (Figure 4.8C-D). Put together these data show that 
Nanog is required neither for the establishment nor the maintenance of primed 
pluripotency. This is in stark contrast with the apparent necessity for Nanog in the 
acquisition of naïve pluripotency (Silva et al., 2009).  
 
It has previously been proposed that Activin promotes self-renewal in hES 
cells and mouse EpiSC through the activation of Nanog (Greber et al., 2010; Vallier 
et al., 2009). In mouse embryos, Nanog tracks Nodal expression in the 
postimplantation epiblast (Figure 4.1; (Brennan et al., 2001)). Moreover, Nodal 
deletion results in premature loss of the pluripotency factors Oct4 and Nanog 
(Brennan et al., 2001; Mesnard et al., 2006).  Unexpectedly, as shown in this chapter, 
EpiSCs can be established and maintained without Nanog. To further investigate 
the signaling requirements involved in the maintenance of primed pluripotency, 
specific inhibitors for Activin (SB431542) or FGF (PD0325901) signaling pathways 
were used. In the presence of an Activin inhibitor (SB431542), explanted epiblast 
tissue lost expression of Nanog:GFP (Figure 4.9A). Interestingly, when an MEK 
inhibitor (PD0325901) was used, no significant effect was on the expression of 
Nanog:GFP (Figure 4.9A). This is consistent with a previous report showing that 
FGF signaling in EpiSC does not cooperate with Smad2/3 to enhance Nanog 
expression (Greber et al., 2010). Moreover, similar to Nanog+/– explants, Nanog–/– 
EpiSC lines treated with Activin inhibitor (SB431542) failed to maintain the 
undifferentiated morphology and downregulated Nanog:GFP (Figure 4.9B-C). It is 





Figure 4. 8 Nanog is dispensable for the derivation and 
maintenance of EpiSC. 
 
(A) Oct4, Sox2 and Nanog immunofluorescence in TC44cre6 (Nanog-/-) and 
Oct4GiP (Nanog+/+) EpiSC lines. 
 
(B) qPCR analysis of in ES-derived EpiSC lines. Analyses were determined relative 
to TATA box-binding protein (TBP) and normalized to ES cells. Results are the 
average 3 independent RNA preparations. 
 
(C) Scoring of germ layer differentiation of the indicated EpiSC cell lines following a 
teratocarcinoma-forming assay.  
 
(D) Masson’s trichrome-stained tumour sections derived from the indicated EpiSC 
lines. ec, embryonal carcinoma cells; c, cartilage; m, skeletal muscle; b, bone; a, 





Figure 4. 9 Signal inhibition in primary explants and EpiSC lines. 
(A) Primary colonies derived from anterior and posterior fragments of E7.5 embryos 
48 hours after explantation showing Nanog:GFP expression in 10 M SB431542 (SB) 
or 1M PD0325901 (PD).  
 
(B) TC44cre6 (Nanog–/GFP) and Oct4GiP (Nanog+/+) EpiSC lines treated with 10 M 
SB431542 or 1 M PD0325901 for 48 hours or 118 hours and examined by 
fluorescence and bright-field imaging.  
 
(C) Flow cytometry analysis of EpiSC lines examined in B at 24 and 48 hours. Wild 




Initially upregulated Nanog:GFP expression at 48 hours, but eventually 
downregulated Nanog:GFP expression and EpiSC morphology by 118 hours (Figure 
4.9B-C). Together, these results indicate that, in EpiSCs, Nanog is a target of Activin 
signaling (Greber et al., 2010; Vallier et al., 2009), but is dispensable for Activin-
dependent self-renewal. 
 
4.5 Role of Oct4 in post-implantation pluripotency 
Based on the observation that primed pluripotency can exist in the absence 
of Nanog, the role of Oct4 was further analysed in post-implantation epiblast 
pluripotency. Oct4 is widely expressed in the post-implantation embryos up until 
the late bud stage (Scholer et al., 1990a; Yeom et al., 1996). However, Oct4 is 
consistently lower in the anterior part of the embryo from the early headfold stage 
(Figure 4.10A, C) (Downs, 2008). Comparison of Oct4 mRNA in the prospective 
forebrain (region 1) and neighbouring tissue (region2), demonstrated that Oct4 
mRNA was consistently lower in the anteriomost region (Figure 4.10A-C). 
Furthermore, Oct4 mRNA declined in both regions with embryonic age (Figure 
4.10C). Next, region 1 and 2 were tested for their ability to reactivate Nanog 
expression in EpiSC culture conditions (Figure 4.10D). Throughout the embryonic 
stages analysed, region 1 showed a lower efficiency of Nanog reactivation than 
region 2 (Figure 4.10D). Moreover, the efficiency of Nanog-reactivation in both 
regions declined with developmental stage (Figure 4.10D). Therefore, similar to ES 
cells, a specific threshold of Oct4 levels may define pluripotency in the post-







Figure 4. 10 Oct4 levels in the pre-somitogenesis epiblast 
correlate with efficiency of Nanog reactivation. 
(A) Whole-mount in situ hybridization of Oct4 mRNA levels in a 1-2s stage embryo. 
Regions 1 and 2 used in B and C are indicated by lines. A, anterior; P, posterior. 
 
(B) Micro-dissection of regions 1 and 2 from a 1-2s stage embryo. 
 
(C) Oct4 mRNA expression in pooled samples of regions 1 and 2 micro-dissected 
from embryos of the indicated stages. Data are mean±s.e.m. 
 
(D) Frequency of Nanog immuno-fluorescent colonies from regions 1 and 2, isolated 
from pooled embryos of the indicated developmental stages and explanted in 
DMEM-F12/KOSR/Activin/bFGF for 48 hours. Number of Nanog+ colonies/total 




In order to test the hypothesis that reduced Oct4 levels results in loss of 
primed pluripotency, Oct4 levels were manipulated in somitogenesis-stage embryos 
using mice carrying a doxycycline inducible Oct4 transgene (TgOct4) (Hochedlinger 
et al., 2005). Anterior (forebrain) and posterior (primitive streak) regions of 
somitogenesis stage TgOct4/+;rtTA/+ embryos were tested for their ability to 
reactivate Nanog and generate EpiSC lines in the presence or absence of 
doxycycline (Figure 4.11). Remarkably, Nanog:GFP was induced within 24 hours in 
explants of E8.5-E10.5 stage embryos cultured in EpiSC conditions exclusively in the 
presence of doxycycline (Figure 4.11A). Moreover, Sox2 and Nanog proteins were 
robustly expressed by 48 hours (Figure 4.11B). Interestingly, the frequency of Nanog 
reactivation declined with the progression of embryonic development (Figure 
4.11A). E13.5-E14.5 embryo explants cultured in the presence of doxycycline did not 
yield Nanog-positive colonies at 48 hours, however, a few Nanog-positive colonies 
appeared after prolonged culture (120 hours; Figure 4.11A). Consistent with this, 
E15.5 embryo explants did not yield Nanog-positive colonies even after 120 hours of 
culture (Figure 4.11A). Therefore, at the onset of somitogenesis Oct4 levels drop 
below the threshold permissive for primed pluripotency, at this point, Nanog 
expression and EpiSC forming potential remain sensitive to raised Oct4 levels, but 
their responsiveness decreases gradually with the progression of embryonic 
development. 
 
Although the speed and efficiency of Nanog reactivation decreased with the 
progression of development, induction of the Oct4 transgene in TgOct4/+;rtTA/+ 







Figure 4. 11 Oct4 mediates Nanog reactivation and restores EpiSC 
formation ability in somitogenesis stage embryos. 
 
(A) Scoring of Nanog+ colonies from explanted TgOct4/+;rtTA/+ forebrain regions 
of the indicated stage embryos cultured in the presence or absence of doxycycline. 
Successful (+) or unsuccessful (–) Nanog:GFP reactivation or EpiSC line derivation 
respectively. Asterisk indicates only one Nanog+ colony was observed after 24h. 
N/D, not determined. Number of colonies scored: E8.5 +Dox, n 68; E8.5 -Dox, 
n=53; E9.5, n=648; E10.5, n=675; E11.5, n=143; E13.5, n=220; E14.5-48 hours, n=283; 
E14.5-120 hours, n=428; E15.5-48 hours, n=145; E15.5-120 hours, n=660. 
 
(B) Nanog and Oct4 or Sox2 immunofluorescence in E8.5 and E9.5 forebrain 
explants in the presence of doxycycline. 
 
(C) TgOct4/+;rtTA/+ EpiSC lines. Top: Bright field images showing morphology of 
representative lines. Bottom: Oct4 and Sox2 immunofluorescence. Box indicates the 
region magnified below. 
 
(D) mRNA expression in established EpiSC lines derived from the indicated 










Figure 4. 12 Growth factor dependency in EpiSC derived from 
somitogenesis stage embryos. 
 
(A) Brightfield images of Oct4-induced E10.5 EpiSC treated for 7 days with a 
selective inhibitor of Transforming Growth Factor-β (TGF-β) superfamily type I 
Activin receptor-like kinase (ALK) receptors (SB431542) or a MEK inhibitor 
(PD0325901). 
 
(B) Gene expression analysis of E10.5 EpiSC after 48 hour treatment with SB431542 
or PD0325901. qPCR analyses were determined relative to TATA box-binding 
protein (TBP) and normalized to untreated E10.5 EpiSC. All qPCR results are the 






Figure 4. 13 JAK inhibition in EpiSC is permissive for the 
expression of pluripotency factors. 
 
(A) Oct4GiP ES cells treated with JAK inhibitor I (Calbiochem 420099; 0.6mM) for 5 
days in GMEMFCS/LIF downregulate Oct4:GFP. FACS analysis (left panel), 
Oct4:GFP fluorescence (middle panel) and fluorescence optics (right panel). 
 
(B) Immunohistochemistry for Esrrb in Oct4-induced E10.5 EpiSC and control ES 
cells. 
 
(C) Immunohistochemistry for Nanog, Oct4, Sox2 and Foxa2 in Oct4-induced E10.5 
EpiSC after their cultured in N2B27/Activin/FGF/JAKi for 1 month. Cells display 
expression of Nanog, Oct4, Foxa2 and Sox2 proteins (20x); robust expression of 




 E9.0-13.5 EpiSC displayed typical undifferentiated morphology, while presenting 
robust expression of Oct4 and Sox2 proteins (Figure 4.11C). Furthermore, E9.0-13.5 
EpiSC lines showed marker gene expression similar to pre-somitogenesis stage 
EpiSC (Figure 4.11D). Importantly, the self-renewal of EpiSC derived from 
somitogenesis stage embryos was dependent on Activin and FGF signaling (Figure 
4.12). Treatment with either an Activin (SB431542) or MEK (PD0325901) resulted in 
the differentiation of E10.5 EpiSC (Figure 4.12A). qPCR analysis showed that lineage 
specific markers were upregulated in E10.5 EpiSC treated with either an Activin 
(SB431542) or MEK inhibitor (PD0325901) (Figure 4.12B). Notably, inhibition of 
JAK/STAT3 signaling did not affect the prolonged culture (~month) of EpiSC 
derived from somitogenesis stage embryos, providing further evidence that these 
are bona fide EpiSC (Figure 4.13). Moreover, teratocarcinoma-forming capacity was 
retained after prolonged culture in the presence of a JAK inhibitor (Figure 4.14). To 
test whether Oct4 induces teratocarcinoma-forming potential without prior 
derivation of EpiSCs, freshly dissected TgOct4/+;rtTA/+ forebrain regions from 5-
11s stage embryos  were grafted to the kidney capsule of wild-type hosts. These 
animals were kept in the presence or absence of doxycycline in the drinking water 
for the duration of the assay (Figure 4.14A-B). After a month, two out of three 
doxycycline-treated grafts had formed large teratocarcinomas containing 
derivatives of all three germ layers (Figure 4.14B-C). Conversely, untreated tissue 
formed only small, differentiated tumours (Figure 4.14B). In order to establish the 
presence of self-renewing cells in the E10.5 EpiSC derived-tumours, secondary 
EpiSC were isolated (Figure 4.15). After 4 passages, these lines showed characteristic 
EpiSC morphology and expressed Oct4, Nanog and Sox2 (Figure 4.15B-C). Thus, 





Figure 4. 14 Enforced Oct4 restores pluripotency in 
somitogenesis-stage embryos. 
 
(A) Teratocarcinoma formation assay using E10.5 EpiSC and freshly dissected 
forebrain (E8.5). E10.5 EpiSC, cultured for a month in JAK inhibitor I, was injected 
under the kidney capsule of recipient mice. Freshly dissected E8.5 forebrain was 
transplanted under the kidney capsule of doxycycline-treated or untreated mice.  
 
(B) Scoring of germ layer differentiation of the indicated EpiSC or embryonic tissue 
following a teratocarcinoma-forming assay. 
 
(C) Representative examples of tissue types contained within teratocarcinomas 
obtained either after engraftment of E10.5 EpiSCs (left) or E8.5 rtTA/+:Oct4/+ 
forebrain (right) under the kidney capsule of Doxycycline-treated mice. ne, 
immature neuroepithilium; ec, embryonal carcinoma; n, mature nervous tissue; kw, 
keratin whorl; b, bone; c, chondrocytes; a, adipose tissue; de, digestive epithelium; 















Figure 4. 15 EpiSC readily generate teratocarcinomas and 2° 
EpiSC. 
 
(A) Freshly dissected kidney with Oct4-induced E10.5 EpiSC derived tissue.  
 
(B) Brightfield image of secondary EpiSCs isolated from E10.5 EpiSC 
teratocarcinoma.  
 
(C) Immunofluorescence for Oct4/Nanog or Sox2/Nanog in secondary EpiSC. 
Secondary EpiSC were cultured for 4 passages in DMEM-
F12KOSR/Activin/bFGF in the absence of doxycycline. Boxed areas are 









can be propagated in vitro. Together these results indicate that a threshold level of 
Oct4 is necessary to sustain primed pluripotency, and suggests that in 
somitogenesis stage embryos, restoration of these levels allows the reactivation of 
the pluripotency network in non-pluripotent cells.  
 
4.6 Changes in nucleosome occupancy accompany the 
loss and reacquisition of pluripotency 
The mechanisms involved in the loss and reacquisition of primed 
pluripotency were investigated. Since chromatin changes participate in gene 
regulation, nucleosome positioning at the regulatory regions of Oct4, Nanog and 
Sox2 was examined (Figure 4.16). Recently it has been shown that active 
promoters/transcription start sites are preferentially isolated using FAIRE (Giresi et 
al., 2007; Nagy et al., 2003).  FAIRE was used to analyse nucleosome-depletion in the 
regulatory regions of the core pluripotency genes (Giresi et al., 2007). FAIRE 
analyses showed prominent changes between pre-somite and early somite stage 
embryos. Interestingly, a reproducibly significant reduction was found in the 
overall accessibility of chromatin at both Oct4 and Nanog regulatory regions in 
whole embryos (Figure 4.16A), which correlated with the observed changes in 
transcript levels (see section 4.1). Chromatin closure was reversed in 2-8s stage 
tissue following Oct4 induction and explantation in EpiSC conditions after 24 hours 
(Figure 4.16B). Notably, Oct4 regulatory elements did not show as extensive 
reopening as Nanog (Figure 4.16B), suggesting differences in the regulation of 





Figure 4. 16 Chromatin changes at pluripotency transcription 
factor genes. 
 
(A) FAIRE enrichment (ratio of test:reference DNA, normalized to -actin) of 
pluripotency transcription factor genes in presomite (LB-EHF; E7.75) and 
somitogenesis-stage (two to eight somites; E8.25) embryos compared with ES cells 
and MEFs. Nanog and Sox2 promoters and the distal enhancer (DE) and proximal 
enhancer (PE) of Oct4 were analysed.   
 
(B) FAIRE of E8.25 embryo explants cultured for 24 hours in EpiSC conditions in the 
presence (+Dox) or absence (–Dox) of doxycycline compared with E8.25 tissue or 
MEFs. Data are mean±s.e.m. Significant differences in A and B were calculated 




provoke chromatin reopening at Nanog in the absence of ectopic Oct4 expression 
and Nanog reactivation (Figure 4.16B). This suggests that growth factors present in  
EpiSC culture conditions can stimulate re-opening of the Nanog promoter, however, 
binding of Oct4 to the Oct/Sox motif is required to stimulate Nanog transcription.  
 
4.7 Progressive decline in pluripotency reactivation 
correlates with increased methylation at Nanog 
The changes in the accessibility of Oct4 and Nanog do not fully account for 
the decreasing efficiency to reactivate Nanog in presence of elevated Oct4 
expression. The previous observation suggests that additional mechanisms may be 
involved in the stable shutdown of pluripotency network. Therefore, the extent of 
CpG methylation at the Nanog promoter was examined in E7.5-E14.5 embryos 
(Figure 4.17). It has previously been shown that the Nanog promoter exhibits higher 
levels of methylation in MEFs compared with ES cells (Imamura et al., 2006). 
Interestingly, it was found that methylation at the Nanog promoter were low at both 
presomite and early somite stages, however, methylation increased as development 
progressed (Figure 4.17). Moreover, analysis of the Oct4-induced E13.5 EpiSC line 
exhibited methylation levels comparable to pre-somite E7.5 embryos (Figure 4.17; 
Bisulfite sequence analysis of the Nanog promoter were performed by Dr. Anestis 
Tsakiridis). These findings indicate that Oct4 mediated reactivation of Nanog and 
acquisition of primed pluripotency is accompanied by a decrease in methylation at 
Nanog. Moreover, increase methylation at Nanog correlates with the progressive 














Figure 4. 17 Methylation analysis of Nanog during embryonic 
development. 
 
Methylation analysis of the Nanog proximal region (grey rectangle) by bisulphite 
sequencing of DNA extracted from whole embryos at the indicated stages. 
Methylation levels in ES cells, MEFs and an established E13.5 forebrain EpiSC line 
are shown for comparison. Filled (methylated) or empty (unmethylated) circles: 
CpGs on individual DNA molecules (horizontal lines). Below each stage, vertical 
bars superimposed on the Nanog promoter represent the proportion of methylated 
CpGs at each position. Green/purple ovals indicate Oct/Sox-binding sites. Arrows 
indicate the transcriptional start site (TSS). Bisulfite sequence analysis of the Nanog 










Previous studies have shown that somatic pluripotency, as indicated by the 
ability to generate teratomas, is lost in the mouse embryo around E8.5 (Beddington, 
1983; Damjanov et al., 1971). However, the precise timing and mechanism involved 
in this process have not been defined. Oct4, Sox2 and Nanog are expressed in the 
pluripotent post-implantation epiblast and in derivative EpiSCs (Brons et al., 2007; 
Tesar et al., 2007). However, little is known about the role of these core pluripotency 
regulators in primed pluripotency. The work presented in this chapter provides 
new insights into the mechanisms involved in the maintenance and loss of post-
implantation pluripotency.    
 
4.8.1 Pluripotency during post-implantation development 
    
Following implantation, the expression of Nanog and Oct4 gradually 
decrease until becoming undetectable at 3-5 somite embryo and 12-15 somite 
embryo, respectively. Conversely, Sox2 expression increases during gastrulation 
and eventually becomes restricted to the neurectoderm. Prior to somitogenesis 
expression of the core pluripotency factors, Oct4, Sox2, and Nanog, is regionalized. 
It is puzzling that in the E7.5 embryo, where pluripotency is a general property of 
the epiblast, these genes are not ubiquitously expressed.  Indeed, three expression 
domains can be identified at E7.5, a Sox2-Oct4 domain at the distal-anterior part of 
the epiblast, a Nanog-Oct4 domain in the posterior-proximal region, and a region in 
which all of these three markers overlap, forming a diagonal band from anterior-




corresponds to neurally fated cells, therefore, it is not surprising that Nanog is 
down-regulated in this region as it is well documented that it blocks neural 
differentiation (Ying et al., 2003b). On the other hand, Nanog-Oct4 co-occupy a 
domain that seems to mark non-neural fate. Nonetheless, these regions are all 
pluripotent when tested by teratocarcinoma assays or EpiSC derivation. This 
suggests that at E7.5 pluripotency is latent, but not an overt property of epiblast 
cells.   
 
Nodal expression in the primitive streak disappears just before the stable 
inactivation of Nanog. It is therefore possible that Nodal could be responsible for 
the restricted expression of Nanog in the embryo, and its loss could contribute to the 
disappearance of Nanog expression. In support of this, Nanog:GFP expression in 
cells explanted in EpiSC conditions is dependent on stimulation of the Activin 
signaling pathway and moderately affected by the FGF pathway.  Moreover, the 
null mutants for Nodal show a downregulation in Nanog expression (Mesnard et 
al., 2006). Therefore, Nanog expression in the post-implantation epiblast is likely to 
depend on Nodal signaling.  
 
Given the fact that most cells are fate-restricted at E7.5 and that in the adult 
pluripotent cells are neoplastic, it is intriguing that the embryo preserves 
pluripotency long after it is required.  In principle there are three reasons as to why 
this occurs: (1) the embryo requires pluripotency until LHF stage, (2) pluripotency 
must be switched off before the onset of somitogenesis, (3) the downregulation of 
pluripotency gene expression tracks a major shift in cell states and is merely a 




pluripotency in the epiblast occurs a full day after lineage restriction (Lawson et al., 
1991; Tzouanacou et al., 2009).  This suggests that pluripotency is not required for 
development up until somitogenesis, but rather that it is necessary to extinguish 
pluripotency by this time. Since FGF and activin-like signaling control region-
specific patterning during somitogenesis (Kawasumi et al., 2011; Mariani et al., 2008; 
Naiche et al., 2011; Suzuki-Hirano et al., 2005), the primary rationale for extinction 
of pluripotency may be to allow orderly progression of organogenesis with a 
secondary effect being to prevent teratocarcinogenesis. An obvious experiment 
would be to overexpress a core pluripotency factor like Nanog or Oct4 to test 
whether the maintenance of pluripotency has any negative effects for the 
progression of development. 
 
4.8.2 Nanog is not essential for EpiSC derivation and 
maintenance 
At E7.5, cells in the distal-anterior epiblast that do not express Nanog, 
remain pluripotent when tested for their ability to make EpiSC and 
teratocarcinomas. However, these experiments are not conclusive, since it is not 
possible to exclude the possibility that Nanog is reactivated in these cells. Therefore, 
to consolidate this observation, pluripotent cells genetically depleted for Nanog 
were used. Nanog-null ES cells were differentiated in vitro into EpiSC. This 
categorically showed that Nanog is not essential for the specification and 
maintenance of primed pluripotency. Furthermore, Nanog levels are higher in ES 
cells than in EpiSC (Han et al., 2010; Osorno and Chambers, 2011). It is possible that 




be true that subtle changes in cells are not detected by these assays and more 
quantitative methods may uncover roles for Nanog. One possibility is that in all 
systems, Nanog promotes faster or more efficient self-renewal. It was demonstrated 
that Nanog-null cells have impaired self-renewal when compared to wild type cells 
(Chambers et al., 2007). However, this does not explain the complete disappearance 
of the inner cell mass from Nanog-null diapause embryos (Silva et al., 2009). Nanog 
has been proposed to be necessary to prevent neural differentiation in EpiSC 
(Vallier et al., 2009). Consistent with this hypothesis is the observation that Nanog 
marks the region of the epiblast fated for non-neural tissues. Despite not being 
required for the maintenance of post-implantation pluripotency, Nanog remains a 
reliable indicator of pluripotency 
 
 
4.8.3 Ectopic Oct4 resuscitates somatic pluripotency 
The correlation between loss of pluripotency and Oct4 downregulation, 
prompted us to test the effects of Oct4 re-expression in somitogenesis-stage 
embryos. This has led to the observation of a novel transition state in which cells are 
no longer pluripotent but can rapidly, and efficiently, reacquire pluripotency upon 
re-expression of Oct4. The speed and efficiency of the process is further proof of 
such transition state, since Oct4-mediated reactivation of the pluripotency is far 
more efficient and faster than somatic cell reprogramming. This transition state is 
characterised by a closed chromatin structure at key network regulatory elements, 
and low levels of DNA methylation at Nanog. Methylation progressively increases 




pluripotent cells are eliminated from the somitogenesis-stage embryo. The first is a 
rapid chromatin-based shutdown that is susceptible to perturbation by variation in 
the levels of pluripotency network components, and the second, a slower, more 
permanent, DNA methylation-based stabilization of the non-pluripotent state. 
Importantly, a previous study has shown that ectopic expression of Oct4 in 3-week 
old mice does not result in teratocarcinoma formation, suggesting that pluripotency 










The mouse epiblast has been shown to present at least two distinct 
pluripotent states (Brons et al., 2007; Evans and Kaufman, 1981; Martin, 1981; Tesar 
et al., 2007). ES cells and EpiSC express the core transcription factors Oct4, Sox2 and 
Nanog (Brons et al., 2007; Tesar et al., 2007). However, these populations differ in 
several aspects, such as morphology, clonal propagation abilities, requirements for 
exogenous factors to promote self-renewal and their ability to re-colonize the 
embryo. Global gene expression analysis suggests that the ES cells and EpiSCs 
display differences in their transcription factor circuitry (Brons et al., 2007; Tesar et 
al., 2007). 
 
5.2 ES cells and EpiSC are distinct pluripotent states 
  Nanog expression first appears in vivo around the morula stage, thereafter 
Nanog is strongly expressed in the nascent epiblast of the ICM (Chambers et al., 
2003; Mitsui et al., 2003). In vivo analysis of Nanog-null embryos indicates that 
Nanog is essential for the specification of the pluripotent epiblast (Silva et al., 2009). 




peri-implantation stage (Figure 5.1). This is also recapitulated using a Nanog:GFP 
reporter mouse line (Figure 5.1). Following implantation, Nanog mRNA is 
subsequently detected in the epiblast (Figure 5.1, see also chapter 4). These 
observations are in contrast to the continued expression of Oct4 and Sox2 during 
implantation and suggest that Nanog may have a brake function that must be 
removed in order for the changes in pluripotent phenotype that occur at 
implantation to proceed. 
 
ES cells can be differentiated in vitro into EpiSC by changing the growth 
factors in the medium from LIF/FCS to Activin/FGF (Figure 5.2; (Guo et al., 2009). 
ES cell transcription factors such as Klf2, Klf4, Esrrb, Nr5a2, Tbx3, Rex1 and Nanog 
are downregulated during this transition (Figure 5.2B). Moreover, the rates of 
change in expression of these factors differ. For instance, Klf4 expression plummets 
by day 1. Esrrb expression is reduced to around 30% of its expression by day 1, 
subsequent expression remained low. Klf2 and Rex1 display different dynamics, the 
expression of these genes is halved around days 2-3 and further decreasing by days 
3-4 to around 25% of their expression in ES cells. Nanog and Tbx3 are progressively 
downregulated in the conversion of ES cells into EpiSCs. The expression of Klf2, 
Klf4, Esrrb, Nr5a2 and Rex1 is undetectable in established EpiSC. Sox2, Tbx3 and 
Nanog are expressed at lower levels in EpiSC when compared to ES cells. The levels 
of Oct4 show small changes when ES cells are forced to differentiate into EpiSC 






Figure 5. 1 Nanog expression in peri-implantation embryos. 
 
Nanog:GFP expression during the peri-implantation period. Top panel, Nanog:GFP 
expression in compacted morula. Middle panel, Nanog:GFP expression in early 
(left) and hatched blastocyst (right). Bottom panel, Nanog:GFP expression in E4.5 







Figure 5. 2 Transition from naive to primed pluripotency. 
 
 (A) The developmental changes that occur between the nascent epiblast found in 
the blastocyst and the post-implantation epiblast can be recapitulated in vitro by 
changing growth factor supplements to the medium.  
 
(B) Gene expression changes occurring upon media switch to N2B27/Activin/Fgf. 
qPCR showing the changes that occur to transcription factor mRNAs when ES cells 
differentiate into EpiSC. ES cells were plated in GMEMFCS/LIF. 24 hours later the 
media was switched to N2B27/Activin/bFGF. qPCR analyses were determined 
relative to TBP and normalized to the ES cell level of 1.0. All qPCR results are the 




Flow cytometry analysis of Oct4GiP ES cells (Yeom et al., 1996) 
demonstrated that expression of this pluripotency regulator does not vary 
significantly during the transition from ES cells to EpiSC (Figure 5.3A). TNG ES cells 
(Chambers et al., 2007) were also analysed using the same experimental strategy. 
Nanog:GFP expression was found to gradually decrease as ES cells differentiated 
into EpiSC (Figure 5.4). An even more rapid shift was observed using an Esrrb-
TdTomato reporter line (obtained from Nicola Festuccia). Esrrb-TdTomato 
expression is completely shut off after 4 days of culture in Activin/Fgf (Figure 5.5).   
 
Nanog overexpression hampers the ability of ES cells to differentiate into the 
neural lineage (Chambers et al., 2003; Ying et al., 2003a). Together with the 
observation that Nanog expression is lower in EpiSC (Figure 5.2; Figure 5.4; (Han et 
al., 2010)), this prompted the hypothesis that Nanog downregulation is critical for 
the transition into EpiSC. To achieve this, ES cells that overexpress different levels 
of Nanog were tested for their ability to make EpiSCs (5x Nanog, EF4; 2x Nanog, 
RCN; (Chambers et al., 2003; Chambers et al., 2007; Yates and Chambers, 2005). A 
negative correlation between the Nanog levels and the ability of ES cells to commit 
to an EpiSC state was observed (Figure 5.6). Cells that express 5x the level of Nanog 
fail to display EpiSC morphology after prolonged culture in EpiSC medium (Figure 
5.6A). Two independent ES cell lines that overexpress Nanog were cultured in 
EpiSC media for eight passages and failed to downregulate ES cell-specific 
pluripotency factors, Rex1, Klf4 and Esrrb (Figure 5.6B). Moreover, in contrast to 
controls, ES cell lines overexpressing Nanog resist upregulation of differentiation 








Figure 5. 3 Oct4:GFP expression during the differentiation of ES 
cells into EpiSC. 
 
Flow cytometry analysis of Oct4GiP cells during the differentiation of ES cells to 
EpiSC. Oct4GiP cells were plated on GMEMFCS/LIF, the following day the 
medium was switched to N2B27/Activin/bFGF and harvested every 24 hours for 







Figure 5. 4 Nanog:GFP expression during the transition of ES 
cells into EpiSC. 
 
Flow cytometry analysis of Nanog:GFP cells during the differentiation of ES cells to 
EpiSC. TNG cells were seeded in GMEMFCS/LIF, the following day the medium 








Figure 5. 5 Esrrb:TdTomato expression during the differentiation 
of ES cells into EpiSC. 
 
Flow cytometry analysis on Esrrb:Tdt ES cells during differentiation of ES cells to 
EpiSC. Esrrb-TdTomato cells were seeded in GMEMFCS/LIF, the following day 
the media was switched to N2B27/Activin/bFGF and harvested every 24 hours for 





Since EpiSCs differentiate when exposed to ES cell media (Guo et al., 2009), 
this can be used to assay the effectiveness of differentiation of cells to an EpiSC 
state. Unlike controls, Nanog-overexpressing cells formed ES cell colonies when 
returned to ES cell media, even after prolonged cultured in EpiSC conditions 
(Figure 5.6C). This indicates that forced expression of Nanog in ES cells can block 
their full transition into an EpiSC state.  
 
Similar to Nanog, Esrrb overexpression can confer LIF-independent self-
renewal (Festuccia et al., 2012; Zhang et al., 2008). Therefore the ability of elevated 
levels of Esrrb to prevent the differentiation of EpiSC from ES cells was tested. A 
clonal line of Esrrb overexpressing ES cells (EfEsrrbc1), shown to be capable of 
cytokine independent self-renewal (Festuccia et al., 2012), was tested for their ability 
to commit to an EpiSC state. However, in contrast to Nanog, sustained expression of 
Esrrb in ES cells did not block differentiation into EpiSC. Two clones of E14Tg2a 
overexpressing Esrrb (EfEsrrbc1 and EfEsrrbc2; ES cells generated by Dr. Adam 
Yates) were cultured in media supplemented with Activin/Fgf for more than 3 
passages. Without exception all the clones tested displayed EpiSC morphology 
(Figure 5.7A). Furthermore, gene expression analysis indicated that these cells 
upregulated expression of lineage specific markers, while switching off ES cell 
specific markers (Figure 5.7B). Ectopic expression of Esrrb in ES cells is insufficient 











Figure 5. 6 Sustained Nanog expression blocks EpiSC 
differentiation. 
 
(A) Brightfield images of cells overexpressing Nanog 5-fold (5x Nanog; EF4 cells), 2-
fold (2x Nanog; RCN), and a control line with wild type Nanog levels (wild type ES; 
Oct4GiP), after culture in N2B27/Activin/bFGF for 8 passages.  
 
(B) Cell lines that overexpress Nanog retain the ability to self-renew in stringent ES 
cell culture conditions; after 8 passages in N2B27/Activin/bFGF cells were replated 
in GMEMFCS/LIF and colonies scored for expression of the ES cell marker, 
alkaline phosphatase (AP). 
 
(C) Nanog overexpression prevents downregulation of ES cells specific transcription 
factors. qPCR showing mRNA levels of ES cell and EpiSC markers. qPCR analyses 








Figure 5. 7 Esrrb overexpression does not prevent transition to 
EpiSC pluripotency. 
 
(A) qPCR for Esrrb in E14Tg2a and EfEsrrbc1 ES cells. The error bars are the SD of 3 
technical replicates of one single experiment. EfEsrrbc1 ES cells were generated by 
Dr. Adam Yates. 
 
(B) Brightfield images of EfEsrrbc1 cells cultured in GMEMFCS/LIF or 
N2B27/Activin/FGF for 3 passages. Cells grown in GMEMFCS/LIF display an ES 
cell morphology, whereas the cells grown in N2B27/Activin/bFGF display typical 
EpiSC morphology.  
 
(C) Gene expression analysis of E14Tg2a and EfEsrrbc1 cells passaged in 
N2B27/Activin/bFGF for 5 passages. E14Tg2a and EfEsrrbc1 ES cells were plated at 
a density of 4 x 104 on fibronectin-coated plates and withN2B27/Activin/bFGF. 
Cells were passaged every 4-5 days using accutase and replated at a 1:10 ratio. 
qPCR analyses were determined relative to TATA box-binding protein (TBP) and 
normalized to the parental ES cells. All qPCR results are shown as the average of 






5.3 Reversion of EpiSC to an ES cell state by Esrrb expression 
 
ES cells pluripotency can be restored in EpiSC by the overexpression of 
several transcription factors ES cell regulators such as Klf4, Klf2, Stat3, Nr5a 
receptors and Nanog (Guo and Smith, 2010; Guo et al., 2009; Hall et al., 2009; Silva 
et al., 2009; Yang et al., 2010). The overexpression of these factors alone is not 
sufficient to re-establish ES cell pluripotency, but must be accompanied by a switch 
into LIF containing media. A pre-requisite for the induction of an ES cell state is the 
removal of Activin and FGF (Hall et al., 2009). This suggests that in this context, 
extrinsic cues have a dominant effect over intrinsic factors on cell fate.  
 
Esrrb is absent from EpiSC, but it is expressed in the undifferentiated ES 
cells (Figure 5.2; Figure 5.5). To test whether Esrrb can revert EpiSC to an ES cell 
phenotype, a system for episomal transduction and expression of cDNAs in EpiSC 
was used (Figure 5.8A). This system requires the cDNA of interest to be cloned into 
a plasmid containing the polyoma origin of replication. This allows extra-
chromosomal replication in cells expressing the polyoma large T antigen (PyLT 
(Figure 5.8B)). An advantage of this expression system is that the plasmid does not 
integrate into the genome. Supertransfectable E14/T and TNG/T ES cells were 
differentiated into EpiSC, and subsequently, tested for their ability to be 
supertransfected (Figure 5.8). Since EpiSC propagate poorly at clonal density, a 
modified protocol for the supertransfection of the cells was established. The day 
following transfection the cells were dissociated, and seeded at a 7-fold higher 






Figure 5. 8 Episomal expression system in EpiSC. 
 
(A) Experimental strategy for the episomal vector expression in EpiSC. 
 
(B) pPyCAGIP plasmid containing the polyoma origin of replication. cDNA is 
cloned directionally in place of the stuffer fragment within a transcription unit 
linked to the puromycin resistance gene (pac) through an IRES. 
 
(C) Fluorescence and brightfield images of EpiSC with episomal expression of the 
vector pPyCAG-DSred-IP. The inset depicts a magnification of the boxed area in the 
left and middle images. 
 
(D) Colony forming assays comparing episomal expression system in ES cells and 
EpiSC. 1 x 106 ES cells or EpiSC expressing PyLT were transfected with vector 
pPyCAG-DSred-IP in GMEM/FCS/LIF or N2B27/Activin/bFGF respectively. The 
following day the ES cells were collected with trypsin, while the EpiSC were 
harvested with accutase, and replated at a density of 4 x 104 in their respective 
media. The plates were stained for Leishman stain after 7 days and scored 
manually. The mean and SD of at least 3 independent experiments performed in 





Chapter 2). Initial experiments assessed transfection of E14/T EpiSC using 
pPyCAG-DSRED-iP. Following 7 days of selection the vast majority of the cells 
expressed DSred, albeit expression was heterogeneous at the cellular level (Figure 
5.6C). This is typical feature of the episomal expression system (Douglas Colby & 
Ian Chambers, personal communication).  Importantly, the transfection efficiency 
observed for EpiSC was comparable to that obtained for ES cells (Figure 5.8D).  
 
Nanog and Klf4 have been shown to reprogramme EpiSC to naïve 
pluripotency (Guo et al., 2009; Silva et al., 2009). Therefore, the abilities of Nanog, 
Esrrb and Klf4 to mediate the reversion of EpiSCs to an ES cell state were compared. 
Supertransfection of Nanog, Klf4 or Esrrb, coupled with a media switch from 
N2B27/Activin/Fgf to N2B27/2i/LIF, promoted EpiSC reprogramming to ground 
state pluripotency (Figure 5.9). It has recently been reported that Nanog can 
promote the reversion of EpiSC to an ES cell state in the complete absence of 
exogenous factors (Theunissen et al., 2011). Episomal expression of Nanog or Esrrb 
in EpiSC also allows reversion to ES cell pluripotency in the presence of FCS alone, 
an additive that others often eschew for undisclosed reasons (Figure 5.9). Strikingly, 
supertransfection of Nanog and Esrrb in EpiSC allowed reversion to ES 
pluripotency in the complete absence of exogenous growth factors (Figure 5.9). 
Interestingly, episomal expression of Nanog or Esrrb in EpiSC allows reversion to 
ES cell pluripotency in all conditions tested, whereas Klf4 could only reprogramme 
EpiSC in N2B272i/LIF (Figure 5.9; 5.10). Importantly, episomal expression of 
control plasmids, such as an empty vector, did not yield any revertant colonies 








Figure 5. 9 Epi-iPS induction efficiencies by the episomal 
expression of Nanog, Klf4 or Esrrb in different media. 
 
(A) Morphology of primary Epi-iPS colonies formed after transfection of the 
respective episomal vector and cultured in the indicated medium for 7 days. EpiSC 
expressing the polyoma large T-antigen protein were lipofected with episomal 
vectors containing empty vector, Nanog, Klf4 or Esrrb. The next day the cells were 
replated in the indicated media in the presence of puromycin selection.  
 
(B) AP-positive colony formation by Epi-iPS cells. Experiment described in A was 
AP stained and the plates scored. The mean and SD of at least three independent 




As previously mentioned, Nanog expression in EpiSC is lower than in ES 
cells (Figure 5.2B; 5.4). Consistent with this, Nanog:GFP is expressed at low levels in 
EpiSC, but can be detected by flow cytometry (Figure 5.10C).  Therefore, increased 
Nanog:GFP expression could be used as an indicator of successful reprogramming to 
an ES cell state. Episomal expression of Nanog and Esrrb, coupled with a media 
switch to GMEMFCS/LIF, resulted in the appearance of Nanog:GFP+ colonies 
(Figure 5.10B). Nanog:GFP+ colonies were not observed in cells that were transfected 
with Klf4 or control DSred plasmid (Figure 5.10B). Pecam1, a cell surface marker 
expressed in the inner cell mass (ICM)/ES cells and downregulated in the 
epiblast/EpiSC (Hayashi et al., 2008; Robson et al., 2001), was upregulated in with 
episomal expression of Nanog and Esrrb (Figure 5.10C).  
 
Esrrb-induced Epi-iPS colonies were picked and expanded in conventional 
ES cell media. Expansion of the Epi-iPS clones was conducted in the absence of 
selection, since it has been shown in ES that absence of selection leads to episome 
loss (Douglas Colby & Ian Chambers, personal communication). Epi-iPS that had 
lost the plasmid were tested for their re-acquired sensitivity to puromycin and used 
for further studies. The expression of Nanog, Sox2, Klf4 and Tbx3 in Epi-iPS was 
restored to levels observed in ES cells, while Fgf5, an early marker of differentiation 
was downregulated (Figure 5.11A). Crucially, injection of Epi-iPS into blastocyst 
produced viable adult chimaeras, indicating that ectopic expression of Esrrb can 
restore the ability of EpiSC to colonise pre-implantation embryos (Figure 5.11B). 









Figure 5. 10 Epi-iPS induction by the episomal expression of 
Nanog, Klf4 or Esrrb. 
 
(A) Scoring of the AP stained plates following Epi-iPS induction by episomal 
expression of Nanog, Klf4 and Esrrb in GMEMFCS/LIF. The mean and SD of at 
least three independent experiment performed in triplicate are shown.  
 
(B) Morphology and Nanog:GFP expression of primary Epi-iPS colonies formed after 
transfection of the respective episomal vector and cultured in GMEMFCS/LIF for 
7 days.  
 
(C) FACS analysis of Pecam1 expression 7 days after transfection of EpiSC with the 









Figure 5. 11 Episomal Esrrb expression restores chimaera 
competency to EpiSC.  
 
(A) mRNA expression in E14/T EpiSC and Epi-iPS colonies expanded in the 
absence of selection after episomal expression of Esrrb and medium switch into 
GMEMFCS/LIF. Error bars: standard deviation of gene expression in 3 
independent experiments. 
 
(B) Esrrb induced Epi-iPS cell chimaera forming capacity. The number of adult 
chimaeras obtained from two independent blastocyst injections. 
 






It was then investigated whether stable integration of Cre-revertable plasmids could 
be used to reprogram EpiSC. In order to achieve efficient deletion, an EpiSC line 
was derived from the previously described ES cell line ROSA:Cre-ERT2 (RC), that 
constitutively express a tamoxifen inducible Cre recombinase (Cre-ERT2) from the 
ROSA26 (Chambers et al., 2007). The previously described loxP flanked Nanog 
expression plasmid (Chambers et al., 2007) was used to prepare derivative 
Esrrb/Klf4 plasmids (Figure 5.12A). Upon Cre-excision, the transcription factor ORF 
is deleted and GFP is expressed constitutively. Nucleofection introduced the Cre-
revertable plasmids into the RC EpiSC, followed by selection in EpiSC media. The 
overexpression of the different factors in EpiSC was verified using real time PCR 
(Figure 5.12B). Cells were then challenged with a media switch to conventional ES 
media (LIF/FCS). The stable integration of loxP-flanked Nanog, Klf4 and Esrrb 
transgenes into RC EpiSC yielded Epi-iPS colonies (Figure 5.12C). Under these 
conditions Esrrb displayed a higher efficiency than Nanog (5 fold) and Klf4 (9 fold) 
to reprogramme EpiSC (Figure 5.12C). Reverted clones were picked and expanded 
in conventional ES cell media in the presence of selection. Tamoxifen treatment of 
the reverted clones resulted in constitutive GFP expression, indicating successful 
deletion of Esrrb (Figure 5.13A). Flow cytometry analysis revealed that absence of 
GFP expression prior to tamoxifen treatment and the efficiency of deletion following 
a 24hr treatment with tamoxifen (Figure 5.13B, top panel). Pecam and c-kit, cell 
surface markers expressed in undifferentiated ES cells but that are downregulated 
in EpiSC were induced in Epi-iPS and remain unaltered following Cre-excision of 












Figure 5. 12 Stable integration of Nanog, Klf4 or Esrrb allows the 
reversion of EpiSC into an ES-like state. 
 
(A) Schematic diagram of the RC EpiSC line and the Cre revertible vectors that were 
used for stable integration of eGFP, Nanog, Klf4 and Esrrb. 
 
(B) mRNA expression of Nanog, Klf4 and Esrrb in RC EpiSC, fEsrrb (RC + floxed 
Esrrb), fKlf4 (RC + floxed-Klf4) and fNanog (RC + floxed-Nanog) cultured in 
N2B27/Activin/bFGF. Error: Standard deviation of the mean in at least 2 
independent experiments. 
 
(C) Number of alkaline phosphatase positive colonies observed 7 days after 
replating 2 x 105 EpiSC stably transfected with Cre revertible GFP, Nanog, Klf4 and 
Esrrb vectors in N2B27/2i/LIF. Error: Standard deviation of the mean in 3 















Figure 5. 13 Cre-excision of floxed-Esrrb. 
 
(A) Two clones of the Esrrb reverted ES-like cells were treated with 1μM of 
Tamoxifen (Sigma) for 24h to Cre-excise the floxed Esrrb vector. Successful Cre-
excision is demonstrated by the ubiquitous expression of eGFP. The first and third 
rows of panels show the untreated Epi-iPS clones (controls), meanwhile the second 
and fourth panels depict cells treated with 1μM Tamoxifen. 
 
(B) Flow cytometry analysis on untreated and treated Epi-iPS for 24h with 1μM of 
Tamoxifen (top panels). The Epi-iPS were stained before and after Cre excision of 
Esrrb, for the cell surface markers Pecam (middle panel) and ckit (lower panel), 

















Figure 5. 14 Esrrb transgene is dispensable for Epi-iPS self-
renewal. 
 
(A) Morphology in E14Tg2a ES cells, fEsrrb Epi-iPS and f-Esrrb-Cre Epi-iPS plated 
at clonal density in GMEMFCS in the presence of LIF or LIF antagonist. 
 
(B) Quantification of the experiment described in A. Error bars are the standard 














Figure 5. 15 Epi-iPS cre-revertants display heterogeneous 
expression of key pluripotency markers. 
 
Immunohistochemistry for Klf4, Esrrb, Nanog, Sox2 and Oct4 proteins in Epi-iPS 
Cre-revertants. The Epi-iPS-Cre cells were plated at low density (5000 cells) into 4-
well plates, the next day the cells were fixed using 4% PFA. The images were taken 






The self-renewal of Esrrb-derived Epi-iPS showed reduced cytokine dependency 
before tamoxifen treatment, whereas cytokine dependence was restored in Cre-
revertants (Figure 5.14). Similar to ES cells, Cre-revertants displayed heterogeneous 
expression of ES cell transcription factors Nanog, Klf4 and Esrrb (Figure 5.15). 
 
5.4 Nanog-null EpiSC can be reverted back to naïve 
pluripotency 
 Next it was tested whether Nanog-/- EpiSC could be reprogrammed with 
defined factors (Figure 5.16A). Uncut, circular, plasmid DNA containing Nanog, 
Klf4 or Esrrb were lipofected into Nanog-/- EpiSC and following two days cells were 
transferred to N2B27/2i/LIF. Transient expression of Nanog and Esrrb, but not 
Klf4, combined with a media change to N2B27/2i/LIF, yielded Epi-iPS colonies 
(Figure 5.16B).  
 
Further confirmation that Esrrb could reprogram EpiSC to an ES cell state in 
the absence of Nanog was obtained using a doxycycline-inducible expression 
system (Figure 5.17; 5.18; 5.19). ES cells in which expression of Nanog or Esrrb could 
be induced from the same genetic locus in a Nanog-/- background had been 
developed in the Chambers’ lab (Figure 5.17; cells provided by Nicola Festuccia). A 
three-fold overexpression of Nanog or Esrrb compared to wildtype ES cells was 
obtained (Figure 5.17B, C). The 44iN and 44iE ES cells were converted into EpiSC by 







Figure 5. 16 Transient expression of Nanog or Esrrb mediates 
EpiSC reprogramming. 
 
(A) Experimental strategy for EpiSC reprogramming using transient expression of 
defined factors. 
 
(B) Transient expression of Nanog or Esrrb in EpiSC and a media switch to 
N2B27/2i/LIF promotes reversion to an ES cell state. Top panel: representative AP 






the presence or absence of doxycycline and stained the plates for alkaline 
phosphatase after 7 days. Reverted colonies were obtained in the plates in which 
Nanog was induced. Interestingly, Epi-iPS colonies were also readily generated in 
the plates in which Esrrb was induced (Figure 5.18A). Using an inducible system 
allowed determination of the minimum exposure period necessary for the 
reprogramming of Nanog-/- EpiSC. Therefore, we plated the 44iN and 44iE EpiSC 
into LIF/FCS with different exposures periods of doxycycline. AP-positive colonies 
were obtained after as little as 24 hour induction of Nanog or Esrrb, with a clear 
positive correlation between the period of exposure and the number of reverted 
colonies (Figure 5.18A, B). Importantly, no reverted colonies were obtained in plates 
that were not induced with doxycycline (Figure 5.18A, B). Induced 44iN displayed a 
higher number of reverted colonies than the 44iE, suggesting that Nanog was more 
efficient than Esrrb in reprogramming of Nanog-null EpiSC (Figure 5.18A, B). Esrrb-
induced reverted Nanog-/- clones were picked and expanded in conventional ES cell 
media in the absence of doxycycline. Importantly, the majority of the 44iE Epi-iPS 
cells had reacquired an ES cell morphology and re-expressed Nanog:GFP to an ES 
cell level (Figure 5.19A). Moreover, the 44iE Epi-iPS had reacquired the ability to 
self-renew in stringent ES culture conditions, such as BMP/LIF and 2i/LIF (Figure 
5.19B). Gene expression analysis revealed that the 44iE Epi-iPS had downregulated 
the early marker of differentiation Fgf5, and re-acquired expression of Sox2, Klf4 
and Tbx3 to ES cell levels (Figure 5.19C). Finally, when these cells were injected 












Figure 5. 17 Nanog-null ES cells were engineered to express 
Nanog or Esrrb in a doxycycline inducible manner. 
 
(A) Scheme depicting the genetic modifications in the doxycycline-inducible 44iN 
and 44iE ES cells. ES cell lines (44iN and 44iE) were generated by Nicola Festuccia).  
 
(B) qPCR showing the total mRNA levels for Nanog in 44iN, parental line 
TβC44Cre6 and E14Tg2a ES cells.  
 
(C) qPCR showing the total mRNA levels for Esrrb in 44iE, parental line TC44Cre6 













Figure 5. 18 Nanog-/- EpiSC can be reverted back to an ES cell 
state using doxycycline-inducible Nanog or Esrrb. 
 
(A) Nanog-null EpiSC that are inducible for Nanog or Esrrb can be reverted back to 
an ES-like state. 44iE and 44iN EpiSC were replated in 9cm dishes at a density of 5 x 
104 in GMEMFCS/LIF in presence of doxycycline for an array of different 
exposure periods (0h, 24h, 72h, 120h and 168h). After 7 days of culture the plates 
were stained for alkaline phosphatase.  
 
(B) Graph depicting the reprogramming efficiency of 44iE and 44iN EpiSC with 
different exposures periods of doxycycline described in A. The plates were stained 
for alkaline phosphatase after 7 days and scored manually. The mean and SD of at 







Figure 5. 19 Doxycycline-inducible Esrrb restores ES cell 
pluripotency to Nanog-null EpiSC. 
(A) Bright field and Nanog:GFP images of 44iE ES cells, EpiSC and Epi-iPS cells. 
 
(B) Reverted Nanog-null ES-like cells can self-renew in serum free conditions in 
N2B27 supplemented either with BMP/LIF or 2i/LIF. 
 
(C) mRNA expression in 44iE EpiSC and Epi-iPS colonies expanded in the absence 
of doxycycline. Error bars: standard deviation of gene expression in 3 independent 
experiments.  
 
(D) 44iE Epi-iPS cell chimaera forming capacity. The number of adult chimaeras 
obtained from two independent blastocyst injections. 
 
(E) Chimaeric mouse obtained from a blastocyst injection with the Esrrb-induced 





ES cells and EpiSCs express the core pluripotency factors Oct4, Sox2 and 
Nanog and this is consistent with their tissue of origin. Nevertheless, ES cells and 
EpiSCs are two distinct pluripotent populations since they show differences in their 
growth factor responsiveness, morphology and their abilities to undergo clonal 
propagation and re-colonize embryos. It is possible to harness this differential 
growth factor responsiveness to convert ES cells into EpiSCs simply by switching 
the media composition and passaging. Alternatively, EpiSC can be reverted back to 
ES cell pluripotency through the individual overexpression of a small number of 
transcription factors. Although the inter-conversion of ES cells and EpiSCs has been 
documented, further analysis of the changes that occur during such transitions may 
be informative. The current chapter deals with the transcription factor requirements 
for the transitions between ES cells and EpiSCs.  
 
5.5.1 Conversion of ES cells into EpiSCs  
Several studies have placed Nanog at the cusp of the pluripotency network 
regulating ES cell self-renewal (Chen et al., 2008; Ivanova et al., 2006; Loh et al., 
2006). Moreover, Nanog levels show a solid positive correlation with the self-
renewal efficiency of ES cells (Chambers et al., 2003; Chambers et al., 2007). It has 
been shown that following the specification of the naïve epiblast, Nanog is 
downregulated prior to implantation (E4.5) and subsequently re-expressed at the 
egg cylinder stage (Chambers et al., 2003; Hart et al., 2004; Osorno et al., 2012). 
Analyses of peri-implantation embryos using Nanog:GFP mice indicate that, indeed, 




(see Section 5.2). This transition was recapitulated in vitro by culturing ES cells in 
media supplemented with growth factors that support EpiSC self-renewal. An early 
event during this transition is the reduction in Nanog levels. Interestingly, several 
prominent Nanog target genes, such as Esrrb and Klf4 (Festuccia et al., 2012), are 
downregulated during the early stages of differentiation (see Section 5.2). It is 
possible that the changes in expression of Esrrb and Klf4 are a direct consequence of 
Nanog dowregulation. Indeed, when Nanog overexpressing cells (Chambers et al., 
2003; Chambers et al., 2007) are cultured in EpiSC media a negative correlation was 
found between the Nanog levels and the ability of ES cells to commit to an EpiSC 
state. Nanog overexpressors resisted the upregulation of differentiation genes and 
failed to downregulate ES cell specific markers such as Rex1, Esrrb and Klf4. Even 
after prolonged passage in EpiSC media, Nanog overexpressors retained the ability 
to self-renew in ES cell media. Although Nanog overexpressors cultured after 
prolonged passage in N2B27/Activin/FGF retain the ability to self-renew in 
GMEMFCS/LIF, the colony forming capacity is lower than that obtained with its 
ES cells counterparts (see section 5.2). This observation may be due to a combination 
of factors: (1) low plating efficiency, (2) higher cell death and/or (3) reduced self-
renewal efficiency. Future work will no doubt help clarify the functional differences 
between the cell types.  
 
It has been shown that Klf4 overexpression does not block differentiation of 
ES cells into EpiSCs (Guo et al., 2009). Moreover, Esrrb overexpressing cells could 
not recapitulate the effect of sustained Nanog expression during the induction of 
EpiSC (see Section 5.2). This feature seems unique to Nanog since cells 




levels seem to play a key role in the specification of the pluripotent state of the cells. 
The mechanisms through which Nanog defines the pluripotent state are likely to 
involve Nanog target genes. It is likely that the in vivo and in vitro downregulation 
of Nanog results in the removal of Nanog target genes that are essential for 
maintaining naïve pluripotency. 
 
5.5.2 Esrrb reverts EpiSC to ES pluripotency 
Sox2 and Nanog are expressed at lower levels in EpiSC when compared to 
ES cells (Han et al., 2010; Osorno and Chambers, 2011). Several transcription factors 
reported to be involved in ES cell self-renewal are not expressed in EpiSC, these 
include Esrrb, Klf4, Klf2 and Nr5a2 (Guo and Smith, 2010; Ivanova et al., 2006; Jiang 
et al., 2008; Niwa et al., 1998). Furthermore, EpiSC express lower levels of Nanog, 
Tbx3, LIF receptor and Stat3 (Figure 5.2; Figure 5.4; (Han et al., 2010; Yang et al., 
2010). Interestingly, the overexpression of Klf4, Klf2, Nr5a2 and Stat3, combined 
with a media switch, can revert EpiSC to ES cell pluripotency (Guo and Smith, 2010; 
Guo et al., 2009; Hall et al., 2009; Yang et al., 2010). Naïve pluripotency can also be 
re-instated by elevating the levels of Nanog in EpiSCs. These observations 
prompted us test the ability of Esrrb to reprogramme EpiSCs to naïve pluripotency. 
Strikingly, side-by-side comparison revealed that Esrrb surpasses Nanog and Klf4 in 
the efficiency to induce ES cell pluripotency in EpiSC. Interestingly, Klf4 
overexpression was only able to reprogramme EpiSC to ES cell pluripotency in the 
presence of exogenous LIF and the combined inhibition of GSK3 (CHIR99021/MEK 
(PD0325901) (Han et al., 2011; Silva et al., 2009). In contrast, Nanog and Esrrb 




(Theunissen et al., 2011) can relieve the requirement for exogenous LIF during the 
reversion of EpiSCs to naïve pluripotency. Strikingly, episomal expression of Nanog 
or Esrrb induced the formation of Epi-iPS in the complete absence of exogenous 
growth factors. This indicates that Nanog and Esrrb are potent inducers of ES cell 
pluripotency in EpiSC. On the other hand, the limited ability of Klf4 to 
reprogramme EpiSC suggests that this transcription factor cannot re-instate ground 
state pluripotency alone, but rather may need the presence/absence of downstream 
targets of GSK3, MEK or both. The above results suggest that Esrrb and Nanog are 
functionally similar in the context of EpiSC reprogramming. Such a functional 
overlap could be caused by the activation of a similar transcriptional programme 
during the induction of naïve pluripotency.  
 
5.5.3 Esrrb can reverts Nanog-/- EpiSC to ES pluripotency 
 It was demonstrated in Chapter 4 that Nanog is not essential for the 
derivation and maintenance of EpiSC. To consolidate the notion that Esrrb can 
functionally substitute for Nanog, we tested the ability of Esrrb to reprogramme 
Nanog-/- EpiSC. Strikingly, Esrrb was able to restore naïve pluripotency in cells 
genetically depleted of Nanog. This is in stark contrast to the observation that Klf4, 
another Nanog target gene (Festuccia et al., 2012), is unable to reprogramme  
Nanog-/- cells. This reinforces the notion that Esrrb shows a high degree of 
functional overlap with Nanog. Interestingly, in the context of reprogramming in a 
Nanog-null background, Esrrb showed a lower reprogramming efficiency of EpiSC 
than Nanog. Together these observations suggests that Esrrb and Nanog act 












The ability of a single cell to generate every cell type in the adult organism 
has been termed as pluripotency. In vivo, pluripotent cells exist transiently in the 
epiblast of the developing embryo and in rare tumour cells. Pluripotent cells have 
been isolated from the pre-implantation and post-implantation epiblast (Brons et al., 
2007; Evans and Kaufman, 1981; Martin, 1981; Tesar et al., 2007). The in vitro 
derivatives of these, ES cells and EpiSCs respectively, also express the core 
pluripotency factors Oct4, Sox2 and Nanog. 
 
6.1 Cellular heterogeneity 
It has recently been shown that chemical inhibition of GSK3 (CHIR99021) 
and MEK (PD0325901), combined with stimulation with LIF (2i/LIF), stabilizes the 
pluripotency network and promotes robust self-renewal (Ying et al., 2008). It has 
been hypothesized that perturbations that compromise the stability of this network 
may prime ES cells towards differentiation (Ying et al., 2008). Relevant to this is the 
finding that Nanog fluctuates between states of high Nanog expression, associated 
with high self-renewal efficiency, and low Nanog expression, associated with 
increased differentiation propensity (Chambers et al., 2007). Together these 
observations postulate Nanog as the key factor mediating the stability of the 
pluripotency network. Consistent with this, it has been reported that FGF/ERK 




Kunath et al., 2007; Stavridis et al., 2007) and it has been shown that this signaling 
negatively regulates Nanog expression (Hamazaki et al., 2006). Furthermore, MEK 
inhibition (PD184352) promotes the upregulation of Nanog, thus promoting self-
renewal (Silva et al., 2009; Ying et al., 2008). In this context, Chapter 3 provides new 
insight into the role of FGF/ERK signaling in the induction of heterogeneous Nanog 
expression. During the early stages of differentiation, FGF/ERK signaling is 
required to destabilize the pluripotency network, thereby generating a balanced 
Nanoghigh/Nanoglow population. To clarify whether ERK signaling promotes 
differentiation through Nanog modulation, an obvious experiment would be to test 
the effects of MEK inhibition in Nanog-null ES cells. If the proposed model holds 
true one would predict that, in the absence of Nanog, MEK inhibition would not 
enhance self-renewal. 
 
6.1 Gene regulatory networks governing pluripotent cell 
states 
Genetic studies have demonstrated that the expression of Oct4, Sox2 and 
Nanog, is essential for the establishment of pluripotency in the embryo. Oct4 and 
Sox2 have been shown to be necessary for the maintenance of pluripotency in ES 
cells (Masui et al., 2007; Niwa et al., 2000), whereas Nanog expression is dispensable 
(Chambers et al., 2007). However, the overexpression of Nanog in ES cells confers 
cytokine-independent self-renewal (Chambers et al., 2003). Oct4, Sox2 and Nanog 
are also expressed in the pluripotent postimplantation epiblast and its in vitro 
derivatives (EpiSCs). However, the role of Oct4, Sox2 and Nanog in primed 




somitogenesis, expression of the core pluripotency factors, Oct4, Sox2, and Nanog, 
is regionalized. It is puzzling that in the E7.5 embryo, where pluripotency is a 
general property of the epiblast, these genes are not ubiquitously expressed. 
Somatic pluripotency is lost in the mouse embryo around E8.5 (Damjanov et al., 
1971), however, the precise timing and mechanism involved in this process has not 
yet been defined. In Chapter 4, it is shown that pluripotency is extinguished at the 
onset of somitogenesis, coincident with reduced expression and chromatin 
accessibility of Oct4 and Nanog. Interestingly, pluripotency tracks the in vivo level of 
Oct4, but this correlation does not hold true for Nanog. Indeed, ectopic Oct4 
expression in somitogenesis-stage tissue provokes rapid reopening of Oct4 and 
Nanog chromatin, Nanog re-expression and resuscitation of moribund pluripotency. 
This competence to re-activate the pluripotency network upon enforced Oct4 
expression is gradually lost with the progression of embryonic development. 
Intriguing is the observation that responsiveness to ectopic Oct4 varies between 
distinct tissues. This could be due to the presence/absence of other key 
pluripotency regulators. It would be interesting to determine whether Oct4-
mediated reactivation of the pluripotency network is dependent on Sox2 expression. 
Additionally, one can ask whether the enforced expression of Nanog can reactivate 
the pluripotency network in somitogenesis stage embryos. 
 
6.3 Lessons from EpiSC 
ES cells and EpiSCs differ in several aspects, such as morphology, clonal 
propagation abilities and their requirements for exogenous factors to promote self-




embryos. EpiSCs, unless selected for rare subpopulations resembling very early 
postimplantation epiblast, are unable to contribute to chimeras in blastocyst 
injection or morula aggregation (Han et al., 2010). EpiSCs are particularly 
interesting because they share many attributes with human ES cells. For instance, 
the culture conditions used to derive and maintain EpiSC were identical to the 
routine culture conditions of hES cells. The observation that the same signals 
promote self-renewal across species suggests that the pathways to pluripotency may 
be evolutionary conserved.  Furthermore, transcriptional analysis also suggests that 
EpiSC are closer to hES cells than to mES cells (Tesar et al., 2007). Although hES 
cells are derived from blastocyst stage embryos, the previous observations strongly 
argues in favour of the notion that hES cells correspond to a more developmentally 
advance pluripotent state, similar to the post-implantation mouse epiblast. It 
remains to be seen whether authentic “human ES cells”, reminiscent of the mouse 
counterpart, can be isolated. 
 
The functional differences between ES cells and EpiSC can also be harvested 
to further our understanding of the pluripotent state. For instance, ES cells can be 
converted into EpiSC by a simply media switch (Guo et al., 2009). The work 
presented in Chapter 5 indicates that during this conversion several ES cells specific 
factors are downregulated. Furthermore, it has been shown that Nanog levels are 
critical for the specification of the pluripotent state of the cells. This is consistent 
with the proposed role of Nanog as modulator of network activity. On the other 
hand, EpiSC can be reverted back to ES cell pluripotency through the 
overexpression of a small number of transcription factors (Guo and Smith, 2010; 




the majority of the factors reported to reprogramme EpiSC also have a known 
function in ES cell self-renewal. The work presented in Chapter 5 shows that the 
Nanog target-gene, Esrrb, is a potent inducer of ES cell pluripotency in EpiSC. Side-
by-side reprogramming experiments revealed that Nanog and Esrrb surpass Klf4 in 
the ability to generated Epi-iPS. Such an experimental approach is potentially very 
useful for the identification and characterization of additional key factors regulating 
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